MEDICINES NOT REIMBURSED THROUGH NATIONAL PRICES AND DIRECTLY COMMISSIONED BY NHS ENGLAND

VERSION 15 PUBLISHED APRIL 2020

SUITABLE FOR SUITABLE FOR SPECIALIST SHARED CARE SHARED CARE CENTRE ONLY BETWEEN PRIOR WITH PRIMARY (includng SPECIALIST APPROVAL CARE (IF DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA STOPPING CRITERIA MONITORING/AUDIT REQUIREMENTS outreach when AND PROFORMA SUPPORTED BY delivered as part SECONDARY REQUIRED LOCAL of a provider CARE VIA PRESCRIBING network) NETWORK COMMITTEE) MODEL HIV IN COMBINATION WITH OTHER ANTI- ABACAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √ RETROVIRAL DRUGS

NHS ENGLAND CLINICAL HIV IN COMBINATION WITH OTHER ANTI- NHS ENGLAND AIDS/HIV ANTIRETROVIRALS COMMISSIONING POLICY: BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √ ABACAVIR + LAMIVUDINE + RETROVIRAL DRUGS B06/P/b/AGREED REGIONAL GUIDELINES DOLUTEGRAVIR (TRIUMEQ®) HIV IN COMBINATION WITH OTHER ANTI- ABACAVIR + LAMIVUDINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √ RETROVIRAL DRUGS ABALOPARATIDE DRUGS AFFECTING BONE MALE AND JUVENILE OSTEOPOROSIS NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ METABOLISM

NHS ENGLAND CLINICAL ABATACEPT JUVENILE ARTHRITIS-PAEDIATRIC NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √ COMMISSIONING POLICY: E03/P/d; TA 373

TA259, 387 (SEE ALSO SSC1438) NICE/NHS ENGLAND POLICY NICE ABIRATERONE CANCER NHS ENGLAND HORMONE ANTAGONISTS ONLY IN ENZALUTAMIDE NAÏVE SACT √ √ PATIENTS

NHS ENGLAND CLINICAL ADALIMUMAB JUVENILE ARTHRITIS-PAEDIATRIC NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √ COMMISSIONING POLICY: E03/P/d; TA 373

ADALIMUMAB UVEITIS - ADULTS NHS ENGLAND CYTOKINE MODULATORS TA460 NICE NICE NICE AUDIT √ √

HIGHLY SPECIALISED HIGHLY SPECIALISED ADALIMUMAB BEHCETS SYNDROME NHS ENGLAND CYTOKINE MODULATORS HIGHLY SPECIALISED CRITERIA ONLY HIGHLY SPECIALISED CRITERIA √ CRITERIA ONLY CRITERIA ONLY ADALIMUMAB HIDRADENITIS SUPPURATIVA NHS ENGLAND CYTOKINE MODULATORS NICE TA 392 NICE NICE NICE AUDIT √ √ ADALIMUMAB PLAQUE PSORIASIS IN CHILDREN NHS ENGLAND CYTOKINE MODULATORS NICE TA 455 NICE NICE NICE AUDIT √ √ VIRAL HEPATITIS (B&C) & NOT ROUTINELY COMMISSIONED ADEFOVIR HEPATITIS B NHS ENGLAND AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ RESPIRATORY SYNCYTIAL VIRUS (CG165) AFATINIB CANCER NHS ENGLAND CANCER EXCLUSION TA310 NICE NICE SACT √

NOT ROUTINELY COMMISSIONED AFLIBERCEPT CANCER NHS ENGLAND CANCER EXCLUSION AS PER IFR APPROVAL AS PER IFR APPROVAL SACT √ (TA307)

DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED AGALSIDASE ALFA FABRY'S DISEASE NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √ DISORDERS CRITERIA ONLY CRITERIA ONLY DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED AGALSIDASE BETA FABRY'S DISEASE NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √ DISORDERS CRITERIA ONLY CRITERIA ONLY ALBUTROPIN ADULT ONSET GROWTH HORMONE GROWTH HORMONE & GROWTH DEFICIENCY NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ HORMONE RECEPTOR ANTAGONIST

ALDESLEUKIN CANCER NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL SACT √ DRUGS AFFECTING THE IMMUNE TA312 AND NHS ENGLAND POLICY ALEMTUZUMAB MULTIPLE SCLEROSIS NHS ENGLAND NICE NICE NICE AUDIT √ √**** RESPONSE STATEMENT 170075P TRUST GUIDELINES: ISLET PRE-TRANSPLANT DRUGS AFFECTING THE IMMUNE ALEMTUZUMAB NHS ENGLAND TRANSPLANTATION (ONLY IF PROVIDED TRUST GUIDELINES TRUST GUIDELINES √ IMMUNOSUPPRESSION RESPONSE AT ZERO DRUG COST) DRUGS AFFECTING THE IMMUNE TRUST GUIDELINES: (ONLY IF PROVIDED ALEMTUZUMAB CLL NHS ENGLAND TRUST GUIDELINES TRUST GUIDELINES SACT √ RESPONSE AT ZERO DRUG COST) HIGHLY SPECIALISED CRITERIA ONLY HIGHLY SPECIALISED HIGHLY SPECIALISED ALEMTUZUMAB BEHCETS SYNDROME NHS ENGLAND CYTOKINE MODULATORS (ONLY IF PROVIDED AT ZERO DRUG HIGHLY SPECIALISED CRITERIA √ CRITERIA ONLY CRITERIA ONLY COST) DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED ALGLUCOSIDASE ALFA POMPE DISEASE NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √ DISORDERS CRITERIA ONLY CRITERIA ONLY DRUGS USED IN METABOLIC ALIPOGENE TIPARVOVEC LIPOPROTEIN LIPASE DEFICIENCY NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ DISORDERS VIRAL HEPATITIS (B&C) & ALISPORIVIR HEPATITIS C NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ RESPIRATORY SYNCYTIAL VIRUS ALPHA MANNOSIDASE DRUGS USED IN METABOLIC ALPHA MANNOSIDASE DEFICIENCY NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ RECOMBINANT HUMAN DISORDERS VASODILATOR ANTIHYPERTENSIVE NHS ENGLAND CLINICAL AMBRISENTAN PULMONARY ARTERIAL HYPERTENSION NHS ENGLAND DRUGS/PULMANORY ARTERIAL NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √ COMMISSIONING POLICY: A11/P/c HYPERTENSION NOT ROUTINELY COMMISSIONED AMIFAMPRIDINE PHOSPHATE LEMS NHS ENGLAND NEUROMUSCULAR DISORDERS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ NHS ENGLAND POLICY: 16009/P

AMIKACIN INHALATION CYSTIC FIBROSIS NHS ENGLAND ANTIBACTERIAL DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

CYSTIC FIBROSIS AMIKACIN LIPOSOMAL NHS ENGLAND ANTIBACTERIAL DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

NUMBER OF PATIENTS TREATED AMPHOTERICIN LIPOSOMAL FUNGAL INFECTION NHS ENGLAND ANTIFUNGALS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √ INDICATIONS WITHIN POLICY DRUGS AFFECTING THE IMMUNE ANABASUM SCLERODERMA NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ RESPONSE NHS ENGLAND CLINICAL ANAKINRA JUVENILE ARTHRITIS-PAEDIATRIC NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √ COMMISSIONING POLICY: E03/P/d PERIODIC FEVERS AND NHS ENGLAND CLINICAL ANAKINRA NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √ AUTOINFLAMMATORY CONDITIONS COMMISSIONING POLICY: 170062P CRYOPYRIN ASSOCIATED PERIODIC CRYOPYRIN ASSOCIATED PERIODIC HIGHLY SPECIALISED HIGHLY SPECIALISED ANAKINRA NHS ENGLAND CYTOKINE MODULATORS HIGHLY SPECIALISED DATABASE √ SYNDROME SYNDROME SERVICE SPECIFICATION CRITERIA ONLY CRITERIA ONLY NHS ENGLAND CLINICAL ANAKINRA ADULT ONSET STILLS DISEASE NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √ COMMISSIONING POLICY: 170056P NUMBER OF PATIENTS TREATED ANIDULAFUNGIN FUNGAL INFECTION NHS ENGLAND ANTIFUNGALS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √ INDICATIONS WITHIN POLICY ANIFROLUMAB SLE NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

APLASTIC ANAEMIA DRUGS USED IN HYPOPLASTIC, ANTILYMPHOCYTE GLOBULIN NHS ENGLAND BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES √ ORGAN TRANSPLANT HAEMOLYTIC, AND RENAL ANAEMIAS

ANTIPSEUDOMONAS AERUGINOSA CYSTIC FIBROSIS NHS ENGLAND ANTIBACTERIAL DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ IgY AS PER BCSH GUIDELINES FOR ANTITHROMBIN III NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES √ SPECIALISED INDICATIONS

ANTITHYMOCYTE APLASTIC ANAEMIA DRUGS USED IN HYPOPLASTIC, NHS ENGLAND BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES √ IMMUNOGLOBULIN ORGAN TRANSPLANT HAEMOLYTIC, AND RENAL ANAEMIAS

ARIMOCLOMOL NIEMANN-PICK DISEASE NHS ENGLAND NEUROMUSCULAR DISORDERS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

NHS England drugs-list v15 2020-2021.xlsx NHSE Commissioned PbRE Drugv15 1 31/03/2020 SUITABLE FOR SUITABLE FOR SPECIALIST SHARED CARE SHARED CARE CENTRE ONLY BETWEEN PRIOR WITH PRIMARY (includng SPECIALIST APPROVAL CARE (IF DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA STOPPING CRITERIA MONITORING/AUDIT REQUIREMENTS outreach when AND PROFORMA SUPPORTED BY delivered as part SECONDARY REQUIRED LOCAL of a provider CARE VIA PRESCRIBING network) NETWORK COMMITTEE) MODEL DRUGS USED IN METABOLIC ASFOTASE ALFA HYPOPHOSPHATASIA NHS ENGLAND HST6 NICE NICE AS PER MAA √ √ DISORDERS VIRAL HEPATITIS (B&C) & ASUNAPREVIR HEPATITIS C NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ RESPIRATORY SYNCYTIAL VIRUS DRUGS AFFECTING THE IMMUNE ATACICEPT SLE NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ RESPONSE

ATALUREN DUCHENNE MUSCULAR DYSTROPHY NHS ENGLAND NEUROMUSCULAR DISORDERS NICE HST3 NICE NICE NORTHSTAR DATABASE √ √

HIV IN COMBINATION WITH OTHER ANTI- ATAZANAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √ RETROVIRAL DRUGS ATAZANAVIR + COBICISTAT HIV IN COMBINATION WITH OTHER ANTI- NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √ (EVOTAZ®) RETROVIRAL DRUGS AS PER NHS ENGLAND AUTOLOGOUS SERUM EYE DROPS DRY EYE NHS ENGLAND BLOOD-RELATED PRODUCTS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √ LETTER/CIRCULAR

AVACOPAN ANCA-POSITIVE VASCULITIS NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

AXITINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA333 (also refer to circular SSC1508) NICE NICE SACT √ AZACITIDINE CANCER NHS ENGLAND MYELODYSPLASTIC SYNDROME TA218 NICE NICE SACT √ NHS ENGLAND CLINCAL AZTREONAM LYSINE CYSTIC FIBROSIS NHS ENGLAND ANTIBACTERIAL DRUGS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √* √* COMMISSIONING POLICY: A01/P/b NOT ROUTINELY COMMISSIONED CYSTIC FIBROSIS (CONTINUOUS AZTREONAM LYSINE NHS ENGLAND ANTIBACTERIAL DRUGS NHS ENGLAND CLINCAL AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ TREATMENT) COMMISSIONING POLICY: 16001/P VASODILATOR ANTIHYPERTENSIVE BARDOXOLONE METHYL PULMONARY ARTERIAL HYPERTENSION NHS ENGLAND DRUGS/PULMANORY ARTERIAL NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ HYPERTENSION CORTICOSTEROIDS AND OTHER BASILIXIMAB RENAL TRANSPLANT NHS ENGLAND TA85 & TA99 NICE NICE √ IMMUNOSUPPRESSANTS BECLABUVIR HEPATITIS C VIRAL HEPATITIS (B&C) & NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ RESPIRATORY SYNCYTIAL VIRUS NHS ENGLAND CLINICAL BEDAQUILINE EXTENSIVELY DRUG RESITANT TB NHS ENGLAND ANTITUBERCULOSIS DRUGS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √ COMMISSIONING POLICY: F04/P/a NHS ENGLAND CLINICAL BEDAQUILINE MULTI DRUG RESITANT TB NHS ENGLAND ANTITUBERCULOSIS DRUGS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √ COMMISSIONING POLICY: F04/P/a MALIGNANT DISEASE AND BEGELOMAB GRAFT VERSUS HOST DISEASE NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ IMMUNOSUPPRESSION DRUGS AFFECTING THE IMMUNE NOT ROUTINELY COMMISSIONED - NICE BELATACEPT RENAL TRANSPLANT NHS ENGLAND NICE TA IN PROGRESS NICE TA IN PROGRESS NICE TA IN PROGRESS √ RESPONSE TA IN PROGRESS DRUGS AFFECTING THE IMMUNE BELIMUMAB SLE NHS ENGLAND NICE TA 397 NICE NICE NICE AUDIT √ √ RESPONSE BENRALIZUMAB ASTHMA NHS ENGLAND ALLERGEN IMMUNOTHERAPY NICE TA 565 NICE NICE NICE AUDIT √ √ BEPERMINOGENE PERPLASMID PERIPHERAL VASCULAR DISEASE NHS ENGLAND GENE THERAPY NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED BETAINE HOMOCYSTINURIA NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √ DISORDERS CRITERIA ONLY CRITERIA ONLY BEVACIZUMAB CANCER CDF ANTINEOPLASTIC DRUGS CDF POLICY CDF CDF SACT √ AS PER NATIONAL PROTOCOL (SEE NF2 AS PER NATIONAL AS PER NATIONAL BEVACIZUMAB NEUROFIBROMATOSIS NHS ENGLAND ANTINEOPLASTIC DRUGS AS PER NATIONAL PROTOCOL √ SERVICE SPEC) PROTOCOL PROTOCOL BICTECRAVIR (IN COMINATION HIV IN COMBINATION WITH OTHER ANTI- NHS ENGLAND CLINCAL WITH EMTRICITABINE AND NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NHS ENGLAND POLICY NHS ENGLAND POLICY HARS DATASET √ RETROVIRAL DRUGS COMMISSIONING POLICY: 170131P TENOFOVIR ALAFENAMIDE) BIMAGRUMAB INCLUSION BODY MYOSITIS NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ BIOTIN MULTIPLE SCLEROSIS NHS ENGLAND VITAMINS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ SYSTEMIC LUPUS ERYTHEMATOSUS BLISIBIMOD NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ (SLE) NOT ROUTINELY COMMISSIONED ORGAN REJECTION POST KIDNEY BORTEZOMIB NHS ENGLAND ANTINEOPLASTIC DRUGS (NHS ENGLAND CLINICAL AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ TRANSPLANT COMMISSIONING POLICY: A07/P/c)

TA129, TA228, TA311, TA378, TA573 CDF POLICY NHS ENGLAND/ NOT ROUTINELY COMMISSIONED NICE NICE BORTEZOMIB CANCER ANTINEOPLASTIC DRUGS SACT √ √ CDF (NHS ENGLAND CLINICAL CDF CDF COMMISSIONING POLICY: 170035P, 170074P)

VASODILATOR ANTIHYPERTENSIVE NHS ENGLAND CLINICAL BOSENTAN DIGITAL ULCERS NHS ENGLAND DRUGS/PULMANORY ARTERIAL NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √ COMMISSIONING POLICY: A13/P/b HYPERTENSION VASODILATOR ANTIHYPERTENSIVE NHS ENGLAND CLINICAL BOSENTAN PULMONARY ARTERIAL HYPERTENSION NHS ENGLAND DRUGS/PULMANORY ARTERIAL NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √ COMMISSIONING POLICY: A11/P/c HYPERTENSION

BOSUTINIB CANCER NHS ENGLAND CANCER EXCLUSION TA 401 NICE NICE SACT √ √

TORSION DYSTONIAS AND OTHER BOTULINUM TOXIN FOCAL SPASTICITY IN CHILDREN NHS ENGLAND AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES AS PER POLICY √ INVOLUNTARY MOVEMENTS INTRAVESICAL USE IN SPINAL CORD TORSION DYSTONIAS AND OTHER BOTULINUM TOXIN*** NHS ENGLAND AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES AS PER POLICY √ INJURY INVOLUNTARY MOVEMENTS ACUTE SENSORINEURAL HEARING BRIMAPITIDE NHS ENGLAND PROTEIN KINASE INHIBITORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ LOSS BRINCIDOFOVIR CYTOMEGALOVIRUS NHS ENGLAND CYTOMEGALOVIRUS INFECTION NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ DRUGS AFFECTING THE IMMUNE BUROSUMAB X LINKED HYPOPHOSPHATAEMIA NHS ENGLAND HST 8 NICE NICE NICE AUDIT √ √ RESPONSE HEREDITARY ANGIOEDEMA - ACUTE NHS ENGLAND CLINICAL C1 ESTERASE INHIBITORS NHS ENGLAND ALLERGIC EMERGENCIES NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √ TREATMENT COMMISSIONING POLICY: B09/P/b HEREDITARY ANGIOEDEMA - NHS ENGLAND CLINICAL C1 ESTERASE INHIBITORS NHS ENGLAND ALLERGIC EMERGENCIES NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √ √ PROPHYLACTIC TREATMENT COMMISSIONING POLICY: 16045/P HEREDITARY ANGIOEDEMA - AS PER NHS ENGLAND CLINICAL C1 ESTERASE INHIBITORS PROPHYLACTIC TREATMENT IN NHS ENGLAND ALLERGIC EMERGENCIES NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √ √ COMMISSIONING POLICY: 16045/P CHILDREN (CINRYZE ONLY) HIV IN COMBINATION WITH OTHER ANTI- CABOTEGRAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ RETROVIRAL DRUGS INBORN ERRORS IN PRIMARY BILE ACID CALCIFIDIOL NHS ENGLAND OTHER ENDOCRINE DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ SYNTHESIS CRYOPYRIN ASSOCIATED PERIODIC NHS ENGLAND CLINICAL CANAKINUMAB NHS ENGLAND IMMUNOMODULATING DRUGS NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √ FEVER SYNDROME COMMISSIONING POLICY: 200209P NOT ROUTINELY COMMISSIONED CANAKINUMAB JUVENILE ARTHRITIS-PAEDIATRIC NHS ENGLAND IMMUNOMODULATING DRUGS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ (TA302)

CANNABIDIOL (AS EPIDIOLEX) DRAVET/LENNOX GESTAUT SYNDROME NHS ENGLAND CANNABINOIDS TA615 & TA614 NICE NICE NICE AUDIT √ √

THROMBOTIC THROMBOCYTOPENIC NOT ROUTINELY COMMISSIONED CAPLACIZUMAB NHS ENGLAND PLATELET DISORDER DRUGS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ PUPURA (TA302)

NHS England drugs-list v15 2020-2021.xlsx NHSE Commissioned PbRE Drugv15 2 31/03/2020 SUITABLE FOR SUITABLE FOR SPECIALIST SHARED CARE SHARED CARE CENTRE ONLY BETWEEN PRIOR WITH PRIMARY (includng SPECIALIST APPROVAL CARE (IF DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA STOPPING CRITERIA MONITORING/AUDIT REQUIREMENTS outreach when AND PROFORMA SUPPORTED BY delivered as part SECONDARY REQUIRED LOCAL of a provider CARE VIA PRESCRIBING network) NETWORK COMMITTEE) MODEL DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED CARGLUMIC ACID UREA CYCLE DISORDERS NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √ DISORDERS CRITERIA ONLY CRITERIA ONLY DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED CARNITINE CARNITINE DEFICIENCY NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √ DISORDERS CRITERIA ONLY CRITERIA ONLY

NUMBER OF PATIENTS TREATED CASPOFUNGIN FUNGAL INFECTION NHS ENGLAND ANTIFUNGALS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √ INDICATIONS WITHIN POLICY

NOT ROUTINELY COMMISSIONED CENEGERMIN NEUROTROPHIC KERATITIS NHS ENGLAND ATMP AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ (TA 532)

CERALIFIMOD MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ LYSOSOMAL STORAGE DISORDER CERLIPONASE ALFA NEURONAL CEROID LIPOFUSCINOSIS NHS ENGLAND HST12 NICE NICE NICE AUDIT √ √ DRUGS CETUXIMAB CANCER NHS ENGLAND ANTINEOPLASTIC DRUGS TA145, TA176 (replaced by TA439), TA473 NICE NICE SACT √ (not TA145) √

CEREBROTENDINOUS DRUGS USED IN METABOLIC NHS ENGLAND CLINICAL CHENODEOXYCHOLIC ACID NHS ENGLAND NHS ENGLAND POLICY NHS ENGLAND POLICY √ √ XANTHOMATOSIS (CTX) DISORDERS COMMISSIONING POLICY 170127P DRUGS USED IN METABOLIC NHS ENGLAND CLINICAL CHENODEOXYCHOLIC ACID PRIMARY BILIARY CIRRHOSIS NHS ENGLAND NHS ENGLAND POLICY NHS ENGLAND POLICY √ √ DISORDERS COMMISSIONING POLICY 170127P INBORN ERRORS IN PRIMARY BILE ACID DRUGS USED IN METABOLIC NHS ENGLAND CLINICAL CHOLIC ACID NHS ENGLAND NHS ENGLAND POLICY NHS ENGLAND POLICY √ √ SYNTHESIS DISORDERS COMMISSIONING POLICY 170127P NUMBER OF PATIENTS TREATED CIDOFOVIR CYTOMEGALOVIRUS NHS ENGLAND CYTOMEGALOVIRUS INFECTION AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √ INDICATIONS WITHIN POLICY PRIMARY AND SECONDARY DRUGS FOR MINERAL BONE TA117 NICE NICE CINACALCET NHS ENGLAND √ HYPERPARATHYROIDISM DISORDERS NHS ENGLAND POLICY 16034/P NHS ENGLAND POLICY NHS ENGLAND POLICY CIPROFLOXACIN INHALATION CYSTIC FIBROSIS NHS ENGLAND ANTIBACTERIAL DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ CIPROFLOXACIN LIPOSOMAL CYSTIC FIBROSIS NHS ENGLAND ANTIBACTERIAL DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ (INHALED) CLADRIBINE MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS TA492, TA616 (Replaces TA492) NICE NICE NICE AUDIT √ √**** PULMONARY LANGERHANS CLADRIBINE NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ HISTIOCYTOSIS CLAZAKIZUMAB ANTIBODY MEDICATED REJECTION NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

NHS ENGLAND CLINICAL HIV IN COMBINATION WITH OTHER ANTI- COBICISTAT NHS ENGLAND AIDS/HIV ANTIRETROVIRALS COMMISSIONING POLICY: NHS ENGLAND POLICY NHS ENGLAND POLICY HARS DATASET √ RETROVIRAL DRUGS F03/P/b/AGREED REGIONAL GUIDELINES

NHS ENGLAND CLINICAL CO-CARELDOPA INTESTINAL GEL PARKINSON'S DISEASE NHS ENGLAND NEURODEGENERATIVE CONDITIONS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √ COMMISSIONING POLICY: D04/P/e NHS ENGLAND CLINICAL NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY COLISTIMETHATE SODIUM CYSTIC FIBROSIS NHS ENGLAND ANTIBACTERIAL DRUGS COMMISSIONING POLICY: A01/P/b √* √* NICE NICE NICE AUDIT TA276 HEREDITARY ANGIOEDEMA - ACUTE NHS ENGLAND CLINICAL CONESTAT ALFA NHS ENGLAND ALLERGIC EMERGENCIES NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √ TREATMENT ONLY COMMISSIONING POLICY: B09/P/b CRIZANLIZUMAB SICKLE CELL DISEASE NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ NICE TA 406, 422 NICE NICE CRIZOTINIB CANCER NHS ENGLAND/CDF PROTEIN KINASE INHIBITORS SACT √ √ CDF (TA 529) CDF CDF CYCLIC PYRANOPTERIN DRUGS USED IN METABOLIC MOLYBDENUM COFACTOR DEFICIENCY NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ MONOPHOSPHATE DISORDERS DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED CYSTEAMINE (MERCAPTAMINE) NEPHROPATHIC CYSTINOSIS NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √ DISORDERS CRITERIA ONLY CRITERIA ONLY DABRAFENIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA321, TA396 & TA 544 NICE NICE SACT √ (not TA321) √ DACLIZUMAB MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ DRUGS USED IN HYPOPLASTIC, RENAL DIALYSIS ONLY, INCLUDING VIA PRODUCT WITH LOWEST DARBOPOETIN ALPHA DIALYSIS-INDUCED ANAEMIA NHS ENGLAND HAEMOLYTIC, AND RENAL ANAEMIAS - OUTPATIENTS, AND ONLY AS PER NICE TRUST GUIDELINES TRUST GUIDELINES √ PROCUREMENT COST TO BE USED IRON OVERLOAD CG114 HIV IN COMBINATION WITH OTHER ANTI- DARUNAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √ RETROVIRAL DRUGS HIV IN COMBINATION WITH OTHER ANTI- DARUNAVIR + COBICISTAT NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √ RETROVIRAL DRUGS VIRAL HEPATITIS (B&C) & DASABUVIR HEPATITIS C NHS ENGLAND TA 365 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √ √ RESPIRATORY SYNCYTIAL VIRUS

DASATINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS NICE TA 425, 426 NICE NICE SACT √ √

NOT ROUTINELY COMMISSIONED DECITABINE CANCER NHS ENGLAND MYELODYSPLASTIC SYNDROME AS PER IFR APPROVAL AS PER IFR APPROVAL SACT √ (TA270) DRUGS USED IN HYPOPLASTIC, IRON CHELATION IN THALASSAEMIA NHS ENGLAND CLINICAL QUALITY DASHBOARD/ NATIONAL DEFERASIROX NHS ENGLAND HAEMOLYTIC, AND RENAL ANAEMIAS - NHS ENGLAND POLICY NHS ENGLAND POLICY √ AND SICKLE CELL COMMISSIONING POLICY 16070/P HAEMOGLOBINOPATHY REGISTRY IRON OVERLOAD DRUGS USED IN HYPOPLASTIC, IRON CHELATION IN THALASSAEMIA NHS ENGLAND CLINICAL QUALITY DASHBOARD/ NATIONAL DEFERIPRONE** NHS ENGLAND HAEMOLYTIC, AND RENAL ANAEMIAS - NHS ENGLAND POLICY NHS ENGLAND POLICY √ AND SICKLE CELL COMMISSIONING POLICY 16070/P HAEMOGLOBINOPATHY REGISTRY IRON OVERLOAD NHS ENGLAND CLINICAL DEFIBROTIDE HEPATIC VENO-OCCLUSIVE DISEASE NHS ENGLAND BLOOD-RELATED PRODUCTS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √ COMMISSIONING POLICY: B04/P/c NHS ENGLAND CLINICAL DELAMANID EXTENSIVELY DRUG RESITANT TB NHS ENGLAND ANTITUBERCULOSIS DRUGS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √ COMMISSIONING POLICY: F04/P/a NHS ENGLAND CLINICAL DELAMANID MULTI DRUG RESITANT TB NHS ENGLAND ANTITUBERCULOSIS DRUGS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √ COMMISSIONING POLICY: F04/P/a DRUGS USED IN HYPOPLASTIC, IRON CHELATION IN THALASSAEMIA NHS ENGLAND CLINICAL QUALITY DASHBOARD/ NATIONAL DESFERRIOXAMINE** NHS ENGLAND HAEMOLYTIC, AND RENAL ANAEMIAS - NHS ENGLAND POLICY NHS ENGLAND POLICY √ AND SICKLE CELL COMMISSIONING POLICY 16070/P HAEMOGLOBINOPATHY REGISTRY IRON OVERLOAD

DEXRAZOXANE ANTHRACYCLINE EXTRAVASATION NHS ENGLAND IMMUNOMODULATING DRUGS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √

NHS ENGLAND CLINICAL DEXRAZOXANE ANTHRACYCLINE CARDIOTOXICITY NHS ENGLAND IMMUNOMODULATING DRUGS NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER IFR APPROVAL √ √ COMMISSIONING POLICY 200204P

NHS ENGLAND CLINICAL DIBOTERMIN ALFA COMPLEX SPINAL SURGERY NHS ENGLAND BONE MORPHOGENETIC PROTEIN NHS ENGLAND POLICY NHS ENGLAND POLICY AUDIT, BSR REGISTRY √ COMMISSIONING POLICY 16063/P

PRIMARY HYPO AND HYPERKALAEMIC DICHLORPHENAMIDE NHS ENGLAND NEUROMUSCULAR DISORDERS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ PERIODIC PARALYSIS

HIV IN COMBINATION WITH OTHER ANTI- DIDANOSINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √ RETROVIRAL DRUGS DIMETHYL FUMARATE MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS TA320 NICE NICE NICE AUDIT √ √**** DIROXIMEL FUMARATE MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ NHS ENGLAND CLINICAL HIV IN COMBINATION WITH OTHER ANTI- DOLUTEGRAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS COMMISSIONING POLICY: B06/P/a/ NHS ENGLAND POLICY NHS ENGLAND POLICY HARS DATASET √ RETROVIRAL DRUGS AGREED REGIONAL GUIDELINES

DOMAGROZUMAB DUCHENNE MUSCULAR DYSTROPHY NHS ENGLAND NEUROMUSCULAR DISORDERS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

NHS England drugs-list v15 2020-2021.xlsx NHSE Commissioned PbRE Drugv15 3 31/03/2020 SUITABLE FOR SUITABLE FOR SPECIALIST SHARED CARE SHARED CARE CENTRE ONLY BETWEEN PRIOR WITH PRIMARY (includng SPECIALIST APPROVAL CARE (IF DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA STOPPING CRITERIA MONITORING/AUDIT REQUIREMENTS outreach when AND PROFORMA SUPPORTED BY delivered as part SECONDARY REQUIRED LOCAL of a provider CARE VIA PRESCRIBING network) NETWORK COMMITTEE) MODEL HIV iN COMBINATION WITH OTHER ANTI- NHS ENGLAND CLINCAL DORAVIRINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NHS ENGLAND POLICY NHS ENGLAND POLICY HARS DATASET √ RETROVIRAL DRUGS COMMISSIONING POLICY: 190137P NOT ROUTINELY COMMISSIONED DORNASE ALFA PRIMARY CILIARY DYSKINESIA NHS ENGLAND MUCOLYTICS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ NHS ENGLAND POLICY 16029/P NHS ENGLAND CLINICAL DORNASE ALFA CYSTIC FIBROSIS NHS ENGLAND MUCOLYTICS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √* √* COMMISSIONING POLICY: A01/P/b

DRISAPERSEN DUCHENNE MUSCULAR DYSTROPHY NHS ENGLAND NEUROMUSCULAR DISORDERS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

DRUGS AFFECTING THE IMMUNE DUPILUMAB ASTHMA NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ RESPONSE HEREDITARY ANGIOEDEMA - ACUTE ECALLANTIDE NHS ENGLAND ALLERGIC EMERGENCIES NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ TREATMENT ONLY ORGAN REJECTION POST KIDNEY PAROXYSMAL NOCTURNAL NOT ROUTINELY COMMISSIONED ECULIZUMAB NHS ENGLAND AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ TRANSPLANT HAEMOGLOBINURIA NHS ENGLAND POLICY: A07/P/b C3 GLOMERULOPATHY (POST PAROXYSMAL NOCTURNAL NHS ENGLAND CLINICAL ECULIZUMAB NHS ENGLAND NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √ TRANSPLANT) HAEMOGLOBINURIA COMMISSIONING POLICY: 16054/P

NHS ENGLAND CLINICAL PAROXYSMAL NOCTURNAL NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY ECULIZUMAB AHUS NHS ENGLAND COMMISSIONING POLICY: E03/PS(HSS)/A √ √ HAEMOGLOBINURIA NICE NICE NICE NICE HST1

NHS NATIONAL SPECIALISED PAROXYSMAL NOCTURNAL PAROXYSMAL NOCTURNAL ECULIZUMAB NHS ENGLAND COMMISSIONING TEAM SERVICE NSCT SERVICE SPEC NSCT SERVICE SPEC NSCT SERVICE SPEC √ HAEMOGLOBINURIA HAEMOGLOBINURIA SPECIFICATION

EDASALONEXENT DUCHENNE MUSCULAR DYSTROPHY NHS ENGLAND NEUROMUSCULAR DISORDERS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

DRUGS AFFECTING THE IMMUNE EDRATIDE SLE NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ RESPONSE HIV IN COMBINATION WITH OTHER ANTI- EFAVIRENZ NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √ RETROVIRAL DRUGS

EFRALOCTOCOG ALFA / EFMOROCTOCOG ALFA / FACTOR HAEMOPHILIA A NHS ENGLAND BLOOD-RELATED PRODUCTS SSC 1652, see also SSC 1818 SSC 1652 SSC 1652 PRODUCTS ON CMU FRAMEWORK √ VIII FC FUSION PROTEIN (Elocta®)

EFTRENONACOG ALFA HAEMOPHILIA B NHS ENGLAND BLOOD-RELATED PRODUCTS SSC 1652 SSC 1652 SSC 1652 PRODUCTS ON CMU FRAMEWORK √

VIRAL HEPATITIS (B&C) & ELBASVIR HEPATITIS C NHS ENGLAND TA 413 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √ √ RESPIRATORY SYNCYTIAL VIRUS DRUGS USED IN METABOLIC ELIGLUSTAT GAUCHER'S DISEASE NHS ENGLAND HST5 NICE NICE HIGHLY SPECIALISED DATABASE √ DISORDERS LYSOSOMAL STORAGE DISORDER MANAGED ACCESS MANAGED ACCESS ELOSULFASE ALFA MUCOPOLYSACCHARIDOSIS IV TYPE A NHS ENGLAND NICE HST2 MANAGED ACCESS AGREEMENT √ √ DRUGS AGREEMENT AGREEMENT ELTROMBOPAG ITP IN CHILDREN NHS ENGLAND PLATELET DISORDER DRUGS AS PER ADULT TA 293 NICE NICE NICE AUDIT √ √ HIV IN COMBINATION WITH OTHER ANTI- ELVITEGRAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES NHS ENGLAND POLICY NHS ENGLAND POLICY HARS DATASET √ RETROVIRAL DRUGS HIV IN COMBINATION WITH OTHER ANTI- ELVUCITABINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ RETROVIRAL DRUGS HAEMOPHAGOCYTIC EMAPALUMAB NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ LYMPHOHISTIOCYTOSIS NHS ENGLAND CLINICAL AS PER BCSH GUIDELINES FOR EMICIZUMAB NHS ENGLAND BLOOD-RELATED PRODUCTS COMMISSIONING POLICY: 170067/P AND NHS ENGLAND POLICY NHS ENGLAND POLICY PRODUCTS ON CMU FRAMEWORK √ SPECIALISED INDICATIONS 170134P NON-ALCOHOLIC STEATOHEPATITIS DRUGS USED IN METABOLIC EMRICASAN NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ (NASH) FIBROSIS DISORDERS HIV IN COMBINATION WITH OTHER ANTI- EMTRICITABINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √ RETROVIRAL DRUGS EMTRICITABINE +TENOFOVIR + HIV IN COMBINATION WITH OTHER ANTI- NHS ENGLAND CLINICAL NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NHS ENGLAND POLICY NHS ENGLAND POLICY HARS DATASET √ DARUNAVIR + COBICISTAT RETROVIRAL DRUGS COMMISSIONING POLICY: F03/P/a EMTRICITABINE +TENOFOVIR + HIV IN COMBINATION WITH OTHER ANTI- NHS ENGLAND CLINICAL NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NHS ENGLAND POLICY NHS ENGLAND POLICY HARS DATASET √ ELVITEGRAVIR + COBICISTAT RETROVIRAL DRUGS COMMISSIONING POLICY: F03/P/a HIV IN COMBINATION WITH OTHER ANTI- EMTRICITABINE +TENOFOVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √ RETROVIRAL DRUGS EMTRICITABINE + TENOFOVIR HIV IN COMBINATION WITH OTHER ANTI- NHS ENGLAND CLINICAL NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NHS ENGLAND POLICY NHS ENGLAND POLICY HARS DATASET √ ALAFENAMIDE RETROVIRAL DRUGS COMMISSIONING POLICY: 16043/P EMTRICITABINE + RILPIVIRINE + HIV IN COMBINATION WITH OTHER ANTI- NHS ENGLAND CLINICAL NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NHS ENGLAND POLICY NHS ENGLAND POLICY HARS DATASET √ TENOFOVIR ALAFENAMIDE RETROVIRAL DRUGS COMMISSIONING POLICY: 16043/P HIV IN COMBINATION WITH OTHER ANTI- ENFUVIRTIDE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √ RETROVIRAL DRUGS VIRAL HEPATITIS (B&C) & ENTECAVIR HEPATITIS B NHS ENGLAND TA153 & IN PROGRESS NICE NICE NICE AUDIT √ RESPIRATORY SYNCYTIAL VIRUS TA316, TA 377 (SEE ALSO SSC1439) NICE/NHS ENGLAND POLICY NICE ENZALUTAMIDE CANCER NHS ENGLAND HORMONE ANTAGONISTS BOTH: ONLY IN ABIRATERONE NAÏVE SACT √ PATIENTS DRUGS USED IN HYPOPLASTIC, RENAL DIALYSIS ONLY, INCLUDING VIA EPOETIN ALPHA, BETA, THETA AND PRODUCT WITH LOWEST DIALYSIS-INDUCED ANAEMIA NHS ENGLAND HAEMOLYTIC, AND RENAL ANAEMIAS - OUTPATIENTS, AND ONLY AS PER NICE TRUST GUIDELINES TRUST GUIDELINES √ ZETA PROCUREMENT COST TO BE USED IRON OVERLOAD CG114 VASODILATOR ANTIHYPERTENSIVE NHS ENGLAND CLINICAL EPOPROSTENOL (5) PULMONARY ARTERIAL HYPERTENSION NHS ENGLAND DRUGS/PULMANORY ARTERIAL NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √ COMMISSIONING POLICY: A11/P/c HYPERTENSION EPRATUZUMAB SLE NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ EPRODISATE AMYLOIDOSIS NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ EPTOTERMIN ALFA COMPLEX SPINAL SURGERY NHS ENGLAND BONE MORPHOGENETIC PROTEIN NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ TA162, TA227, TA 374& IN PROGRESS ERLOTINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS NICE NICE SACT √ NHSE LETTER

NHS ENGLAND CLINICAL ETANERCEPT JUVENILE ARTHRITIS-PAEDIATRIC NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √ COMMISSIONING POLICY: E03/P/d; TA 373

ETANERCEPT PLAQUE PSORIASIS IN CHILDREN NHS ENGLAND CYTOKINE MODULATORS TA455 NICE NICE NICE AUDIT √ √

HYPERPARATHYROIDISM - DIALYSIS DRUGS FOR MINERAL BONE ETELCALCETIDE NHS ENGLAND TA448 NICE NICE √ √ PATIENTS ONLY DISORDERS

ETEPLIRSEN DUCHENNE MUSCULAR DYSTROPHY NHS ENGLAND NEUROMUSCULAR DISORDERS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

HIV IN COMBINATION WITH OTHER ANTI- ETRAVIRINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √ RETROVIRAL DRUGS EVEROLIMUS (AFINITOR®) CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA421, TA432, TA449, TA498 NICE NICE SACT √ √ PREVENTING ORGAN REJECTION IN NOT ROUTINELY COMMISSIONED EVEROLIMUS (CERTICAN®) NHS ENGLAND PROTEIN KINASE INHIBITORS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ LIVER TRANSPLANTATION (TA348) PREVENTING ORGAN REJECTION IN NOT ROUTINELY COMMISSIONED NHS EVEROLIMUS (CERTICAN®) NHS ENGLAND PROTEIN KINASE INHIBITORS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ HEART TRANSPLANTATION ENGLAND POLICY 16016/P SUBEPENDYMAL GIANT CELL NHS ENGLAND CLINICAL EVEROLIMUS (VOTUBIA®) ASTROCYTOMA (SEGA) ASSOCIATED NHS ENGLAND PROTEIN KINASE INHIBITORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √ COMMISSIONING POLICY: 16066/P WITH TUBULAR SCLEROSIS

NHS England drugs-list v15 2020-2021.xlsx NHSE Commissioned PbRE Drugv15 4 31/03/2020 SUITABLE FOR SUITABLE FOR SPECIALIST SHARED CARE SHARED CARE CENTRE ONLY BETWEEN PRIOR WITH PRIMARY (includng SPECIALIST APPROVAL CARE (IF DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA STOPPING CRITERIA MONITORING/AUDIT REQUIREMENTS outreach when AND PROFORMA SUPPORTED BY delivered as part SECONDARY REQUIRED LOCAL of a provider CARE VIA PRESCRIBING network) NETWORK COMMITTEE) MODEL SEIZURES ASSOCIATED WITH SUBEPENDYMAL GIANT CELL NHS ENGLAND CLINICAL EVEROLIMUS (VOTUBIA®) NHS ENGLAND PROTEIN KINASE INHIBITORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √ ASTROCYTOMA (SEGA) ASSOCIATED COMMISSIONING POLICY: 170093P WITH TUBULAR SCLEROSIS NHS ENGLAND CLINICAL RENAL ANGIOMYOLIPOMA ASSOCIATED EVEROLIMUS (VOTUBIA®) NHS ENGLAND PROTEIN KINASE INHIBITORS COMMISSIONING POLICY STATEMENT NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √ WITH TUBULAR SCLEROSIS B14X09L

HOMOZYGOUS FAMILIAL EVINACUMAB NHS ENGLAND LIPID-REGULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ HYPERCHOLESTEROLAEMIA

AS NICE TA 394 HOMOZYGOUS FAMILIAL EVOLOCUMAB NHS ENGLAND LIPID-REGULATING DRUGS (FOLLOW GUIDANCE FOR NICE NICE NICE AUDIT √ HYPERCHOLESTEROLAEMIA HETEROZYGOUS FH)

TREATMENT OF ADULT PATIENTS WITH EX-VIVO EXPANDED AUTOLOGOUS MODERATE TO SEVERE LIMBAL STEM HUMAN CORNEAL EPITHELIAL CELL DEFICIENCY (LSCD), UNILATERAL NHS ENGLAND ATMP TA 467 NICE NICE NICE AUDIT √ √ CELLS CONTAINING STEM CELLS OR BILATERAL, DUE TO PHYSICAL OR (HOLOCLAR) CHEMICAL OCULAR BURNS

AS PER BCSH GUIDELINES FOR FACTOR IX NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES PRODUCTS ON CMU FRAMEWORK √ SPECIALISED INDICATIONS AS PER BCSH GUIDELINES FOR FACTOR VII NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES √ SPECIALISED INDICATIONS AS PER BCSH GUIDELINES FOR FACTOR VIIA NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES PRODUCTS ON CMU FRAMEWORK √ SPECIALISED INDICATIONS AS PER BCSH GUIDELINES FOR FACTOR VIII NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES, see also SSC 1818 BCSH GUIDELINES BCSH GUIDELINES PRODUCTS ON CMU FRAMEWORK √ SPECIALISED INDICATIONS FACTOR VIII INHIBITOR BYPASSING AS PER BCSH GUIDELINES FOR NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES PRODUCTS ON CMU FRAMEWORK √ FACTOR (FEIBA) SPECIALISED INDICATIONS AS PER BCSH GUIDELINES FOR FACTOR XIII NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES PRODUCTS ON CMU FRAMEWORK √ SPECIALISED INDICATIONS NOT ROUTINELY COMMISSIONED FAMPRIDINE MULTIPLE SCLEROSIS NHS ENGLAND NEUROMUSCULAR DISORDERS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √**** NHS ENGLAND POLICY: 16010/P DRUGS AFFECTING THE IMMUNE FEDRATINIB MYELOFIBROSIS NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ RESPONSE

FENFLURAMINE DRAVET DISEASE NHS ENGLAND CENTRAL NERVOUS SYSTEM NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

AS PER BCSH GUIDELINES FOR FIBRINOGEN NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES √ SPECIALISED INDICATIONS FIBROBLAST GROWTH FACTOR 1 SOMATOSTATIN ANALOGUE NHS ENGLAND SOMATOSTATIN ANALOGUES NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ GENE THERAPY TA254 FINGOLIMOD MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NHS ENGLAND POLICY NHS ENGLAND POLICY NICE AUDIT √ √**** NHS ENGLAND POLICY: D04/P/b ANAEMIAS AND SOME OTHER BLOOD FITUSIRAN HAEMOPHILIA A AND B NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ DISORDERS FORIGERIMOD ACETATE SLE NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ HIV IN COMBINATION WITH OTHER ANTI- FOSAMPRENAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √ RETROVIRAL DRUGS NUMBER OF PATIENTS TREATED FOSCARNET CYTOMEGALOVIRUS NHS ENGLAND CYTOMEGALOVIRUS INFECTION AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √ INDICATIONS WITHIN POLICY HIV iN COMBINATION WITH OTHER ANTI- FOSTEMSAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ RETROVIRAL DRUGS GALUNISERTIB CANCER NHS ENGLAND MYELODYSPLASTIC SYNDROME NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED GALSULFASE MUCOPOLYSACCHARIDOSIS NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √ DISORDERS CRITERIA ONLY CRITERIA ONLY NUMBER OF PATIENTS TREATED GANCICLOVIR CYTOMEGALOVIRUS NHS ENGLAND CYTOMEGALOVIRUS INFECTION AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √ INDICATIONS WITHIN POLICY DRUGS AFFECTING THE IMMUNE GANETESPIB CANCER NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL SACT √ RESPONSE GEFITINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA192 NICE NICE SACT √ GEVOKIZUMAB UVEITIS NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ DRUGS USED IN METABOLIC GIVOSIRAN HEPATIC PORPHYRIA NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ DISORDERS

GLATIRAMER MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS TA527 & NHS ENGLAND POLICY: D04/P/b NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER NHSE POLICY √ √****

VIRAL HEPATITIS (B&C) & GLECAPREVIR HEPATITIS C NHS ENGLAND NICE TA 499 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √ √ RESPIRATORY SYNCYTIAL VIRUS METHOTREXATE INDUCED RENAL NHS ENGLAND CLINICAL GLUCARPIDASE NHS ENGLAND POISONING NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ DYSFUNCTION COMMISSIONING POLICY: B15/P/a DRUGS USED IN METABOLIC AS PER NHS ENGLAND CIRCULAR SSC GLYCEROL PHENYLBUTYRATE UREA CYCLE DISORDERS NHS ENGLAND NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ DISORDERS 1881 AND LETTER

GOSURANEMAB SUPRANUCLEAR PALSY NHS ENGLAND CENTRAL NERVOUS SYSTEM NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

GRANULOCYTE-MACROPHAGE ANTIBODY-POSITIVE PULMONARY COLONY-STIMULATING FACTOR NHS ENGLAND DRUGS USED IN NEUTROPENIA NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ ALVEOLAR PROTEINOSIS (LEUKINE® - IMPORT) VIRAL HEPATITIS (B&C) & GRAZOPREVIR HEPATITIS C NHS ENGLAND TA 413 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √ √ RESPIRATORY SYNCYTIAL VIRUS HIV VACCINE HIV INFECTION PROPHYLAXIS NHS ENGLAND VACCINES AND ANTISERA NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED HAEM ARGINATE HEPATIC PORPHYRIA NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √ DISORDERS CRITERIA ONLY CRITERIA ONLY HUMAN ALPHA-1 PROTEINASE EMPHYSEMA NHS ENGLAND DRUGS USED FOR EMPHYSEMA NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ INHIBITOR NHS ENGLAND CLINICAL HUMAN COAGULATION FACTOR X FACTOR X DEFICIENCY NHS ENGLAND BLOOD-RELATED PRODUCTS NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √ COMMISSIONING POLICY:200208P HUMAN HETEROLOGOUS LIVER DRUGS USED IN METABOLIC UREA CYCLE DISORDERS NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ CELLS DISORDERS

HUMAN PARATHYROID HORMONE- MALE AND JUVENILE OSTEOPOROSIS DRUGS AFFECTING BONE NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ RELATED PROTEIN ANALOGUE HYPOPARATHYROIDISM METABOLISM

HIV iN COMBINATION WITH OTHER ANTI- IBALIZUMAB NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ RETROVIRAL DRUGS HEREDITARY ANGIOEDEMA - ACUTE NHS ENGLAND CLINICAL ICATIBANT NHS ENGLAND ALLERGIC EMERGENCIES NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √ TREATMENT ONLY COMMISSIONING POLICY: B09/P/b HEREDUTARY ANGIOEDEMA - NHS ENGLAND CLINICAL ICATIBANT NHS ENGLAND ALLERGIC EMERGENCIES NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √ √ PROPHYLACTIC TREATMENT COMMISSIONING POLICY: 16045/P

IDEBENONE DUCHENNE MUSCULAR DYSTROPHY NHS ENGLAND NEUROMUSCULAR DISORDERS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED IDURSULFASE MUCOPOLYSACCHARIDOSIS NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √ DISORDERS CRITERIA ONLY CRITERIA ONLY

NHS England drugs-list v15 2020-2021.xlsx NHSE Commissioned PbRE Drugv15 5 31/03/2020 SUITABLE FOR SUITABLE FOR SPECIALIST SHARED CARE SHARED CARE CENTRE ONLY BETWEEN PRIOR WITH PRIMARY (includng SPECIALIST APPROVAL CARE (IF DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA STOPPING CRITERIA MONITORING/AUDIT REQUIREMENTS outreach when AND PROFORMA SUPPORTED BY delivered as part SECONDARY REQUIRED LOCAL of a provider CARE VIA PRESCRIBING network) NETWORK COMMITTEE) MODEL VASODILATOR ANTIHYPERTENSIVE NHS ENGLAND CLINICAL ILOPROST (5) PULMONARY ARTERIAL HYPERTENSION NHS ENGLAND DRUGS/PULMANORY ARTERIAL NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √ COMMISSIONING POLICY: A11/P/c HYPERTENSION

IMATINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA70, TA86, TA251, TA326 NICE NICE SACT √

CHRONIC GRAFT VERSUS HOST NHS ENGLAND CLINICAL IMATINIB NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ DISEASE COMMISSIONING POLICY:16069/P IMETELSTAT CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED IMIGLUCERASE GAUCHER'S DISEASE NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √ DISORDERS CRITERIA ONLY CRITERIA ONLY TRANSPLANT REJECTION PREVENTION IMLIFIDASE NHS ENGLAND NO GROUP NAME AGREED NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ IN HLA-SENSITISED PATIENTS HIV IN COMBINATION WITH OTHER ANTI- INDINAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √ RETROVIRAL DRUGS INEBILIZUMAB MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ NHS ENGLAND CLINICAL INFLIXIMAB JUVENILE ARTHRITIS-PAEDIATRIC NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √ COMMISSIONING POLICY: E03/P/d NOT ROUTINELY COMMISSIONED (NHS ENGLAND CLINICAL INFLIXIMAB UVEITIS NHS ENGLAND CYTOKINE MODULATORS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ COMMISSIONING POLICY: D12/P/a & D12/P/a) CONNECTIVE TISSUE DISEASE - NOT ROUTINELY COMMISSIONED - INFLIXIMAB NHS ENGLAND CYTOKINE MODULATORS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ INTERSTITAL LUNG DISEASE POLICY IN PROGRESS INFLIXIMAB CROHN'S DISEASE IN CHILDREN NHS ENGLAND CYTOKINE MODULATORS TA187 NICE NICE NICE AUDIT √ INFLIXIMAB GRAFT VERSUS HOST DISEASE NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ INFLIXIMAB RENAL NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ NOT ROUTINELY COMMISSIONED INFLIXIMAB PULMONARY SARCOIDOSIS NHS ENGLAND CYTOKINE MODULATORS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ NHS ENGAND POLICY 170088P NOT ROUTINELY COMMISSIONED - NHS INFLIXIMAB HIDRADENITIS SUPPURATIVA NHS ENGLAND CYTOKINE MODULATORS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ ENGLAND POLICY 16018/P HIGHLY SPECIALISED HIGHLY SPECIALISED INFLIXIMAB BEHCETS SYNDROME NHS ENGLAND CYTOKINE MODULATORS HIGHLY SPECIALISED CRITERIA ONLY HIGHLY SPECIALISED CRITERIA √ CRITERIA ONLY CRITERIA ONLY INOTERSEN AMYLOIDOSIS NHS ENGLAND UNCLASSIFIED HST9 NICE NICE NICE AUDIT √ √ INTERFERON ALFA HEPATITIS B AND C NHS ENGLAND IMMUNOMODULATING DRUGS TA75 NICE NICE NICE AUDIT √ MIDDLE EAST RESPIRATORY INTERFERON ALFA N3 IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ SYNDROME TA 527, TA624 INTERFERON BETA MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER NHSE POLICY √ √**** NHS ENGLAND POLICY: D04/P/b

CLINICAL GUIDELINES FOR IMMUNOGLOBULIN USE, SECOND EDITION UPDATE (JULY 2011) QUALITY DASHBOARD INTRAVENOUS NORMAL HUMAN INTRAVENOUS NORMAL HUMAN MULTIPLE INDICATIONS NHS ENGLAND IMMUNOGLOBULIN GUIDELINES NATIONAL GUIDELINES NATIONAL GUIDELINES NATIONAL IMMUNOGLOBULIN DATA √ IMMUNOGLOBULINS IMMUNOGLOBULINS PUBLISHED 2019 ON MDSAS WEBSITE BASE NHS ENGLAND CLINICAL COMMISSIONING POLICY 190136P

NUMBER OF PATIENTS TREATED FUNGAL INFECTION (LICENSED ISAVUCONAZOLE NHS ENGLAND ANTIFUNGALS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √ √ INDICATIONS) INDICATIONS WITHIN POLICY NHS ENGLAND CLINICAL IVACAFTOR CYSTIC FIBROSIS NHS ENGLAND MUCOLYTICS COMMISSIONING POLICY: A01/P/c, NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ 16049/P IXAZOMIB AMYLOIDOSIS NHS ENGLAND CANCER EXCLUSION NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ IXAZOMIB MULTIPLE MYELOMA CDF CANCER EXCLUSION CDF (TA 505) CDF CDF SACT √ √ VIRAL HEPATITIS (B&C) & LAMIVUDINE HEPATITIS B NHS ENGLAND CG165 NICE NICE NICE AUDIT √ RESPIRATORY SYNCYTIAL VIRUS HIV IN COMBINATION WITH OTHER ANTI- LAMIVUDINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √ RETROVIRAL DRUGS LANADELUMAB HEREDITARY ANGIOEDEMA NHS ENGLAND ALLERGIC EMERGENCIES TA606 NICE NICE NICE AUDIT √ √

PRODUCT WITH LOWEST LANREOTIDE CANCER NHS ENGLAND SOMATOSTATIN ANALOGUES AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √ PROCUREMENT COST TO BE USED

HIGHLY SPECIALISED HIGHLY SPECIALISED LANREOTIDE CONGENITAL HYPERINSULINISM NHS ENGLAND SOMATOSTATIN ANALOGUES HIGHLY SPECIALISED CRITERIA ONLY √ CRITERIA ONLY CRITERIA ONLY

PRODUCT WITH LOWEST LANREOTIDE*** ACROMEGALY NHS ENGLAND SOMATOSTATIN ANALOGUES AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √ √ PROCUREMENT COST TO BE USED

LANTHANUM CARBONATE ADULT RENAL DIALYSIS ONLY NHS ENGLAND PHOSPHATE BINDING AGENTS TRUST GUIDELINES TRUST GUIDELINES √ LAPATINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL SACT √ LAQUINIMOD MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √**** DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED LARONIDASE MUCOPOLYSACCHARIDOSIS NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √ DISORDERS CRITERIA ONLY CRITERIA ONLY LEBRIKIZUMAB ASTHMA NHS ENGLAND ALLERGEN IMMUNOTHERAPY NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

LENALIDOMIDE CANCER NHS ENGLAND IMMUNOMODULATING DRUGS TA171, TA322, TA587, TA586 NICE NICE SACT √ √

HIGHLY SPECIALISED HIGHLY SPECIALISED LENALIDOMIDE POEMS NHS ENGLAND IMMUNOMODULATING DRUGS HIGHLY SPECIALISED CRITERIA ONLY √ CRITERIA ONLY CRITERIA ONLY HIV IN COMBINATION WITH OTHER ANTI- LERONLIMAB NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ RETROVIRAL DRUGS LETERMOVIR CYTOMEGALOVIRUS NHS ENGLAND CYTOMEGALOVIRUS INFECTION TA 591 NICE NICE NICE AUDIT √ √ LEVOFLOXACIN (INHALED) CYSTIC FIBROSIS NHS ENGLAND ANTIBACTERIAL DRUGS NHS ENGLAND POLICY 170078P NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ LEVOKETOCONAZOLE CUSHING'S DISEASE NHS ENGLAND NOVEL - NO GROUP NAME AGREED NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ HYPONATRAEMIA AND OTHER POSTERIOR PITUITARY HORMONES LIXIVAPTAN NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ ENDOCRINE USES AND ANTAGONISTS HOMOZYGOUS FAMILIAL LOMITAPIDE NHS ENGLAND LIPID-REGULATING DRUGS NHS ENGLAND POLICY 170059P NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ HYPERCHOLESTEROLEMIA LONAFARNIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ HIV IN COMBINATION WITH OTHER ANTI- LOPINAVIR + RITONAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √ RETROVIRAL DRUGS NHS ENGLAND URGENT POLICY LUMACAFTOR AND IVACAFTOR CYSTIC FIBROSIS NHS ENGLAND MUCOLYTICS NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √ STATEMENT 190137P LUSPATERCEPT CANCER NHS ENGLAND MYELODYSPLASTIC SYNDROME NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

GROWTH HORMONE & GROWTH MACIMORELIN GROWTH FAILURE NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ HORMONE RECEPTOR ANTAGONIST

VASODILATOR ANTIHYPERTENSIVE NHS ENGLAND CLINICAL MACITENTAN PULMONARY ARTERIAL HYPERTENSION NHS ENGLAND DRUGS/PULMANORY ARTERIAL NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √ COMMISSIONING POLICY: A11/P/c HYPERTENSION NHS ENGLAND CLINICAL NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY MANNITOL CYSTIC FIBROSIS NHS ENGLAND MUCOLYTICS COMMISSIONING POLICY: A01/P/b √ NICE NICE NICE AUDIT TA266 MARALIXIBAT ALAGILLE SYNDROME NHS ENGLAND NOVEL - NO GROUP NAME AGREED NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

NHS England drugs-list v15 2020-2021.xlsx NHSE Commissioned PbRE Drugv15 6 31/03/2020 SUITABLE FOR SUITABLE FOR SPECIALIST SHARED CARE SHARED CARE CENTRE ONLY BETWEEN PRIOR WITH PRIMARY (includng SPECIALIST APPROVAL CARE (IF DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA STOPPING CRITERIA MONITORING/AUDIT REQUIREMENTS outreach when AND PROFORMA SUPPORTED BY delivered as part SECONDARY REQUIRED LOCAL of a provider CARE VIA PRESCRIBING network) NETWORK COMMITTEE) MODEL HIV IN COMBINATION WITH OTHER ANTI- MARAVIROC NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √ RETROVIRAL DRUGS NOT ROUTINELY COMMISSIONED MARAVIROC NATALIZUMAB INDUCED PML NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NHS ENGLAND POLICY STATEMENT AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ 170040P MARIBAVIR CYTOMEGALOVIRUS NHS ENGLAND CYTOMEGALOVIRUS INFECTION NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ MASITINIB PANCREATIC CANCER/GIST NHS ENGLAND PROTEIN KINASE INHIBITORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

GROWTH HORMONE & GROWTH NHS ENGLAND CLINICAL MECASERMIN GROWTH FAILURE NHS ENGLAND NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √ HORMONE RECEPTOR ANTAGONIST COMMISSIONING POLICY: EO3/P/a

TA431 MEPOLIZUMAB ASTHMA NHS ENGLAND ALLERGEN IMMUNOTHERAPY NICE NICE NICE AUDIT √ √

METRELEPTIN DYSLIPIDAEMIA NHS ENGLAND OTHER ENDOCRINE DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

NHS ENGLAND CLINICAL METRELEPTIN CONGENITAL LEPTIN DEFICIENCY NHS ENGLAND OTHER ENDOCRINE DRUGS NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √ COMMISSIONING POLICY: 170095P AS PER NHS ENGLAND CIRCULAR SSC MEXILETINE NON DYSTROPHIC MYOTONIA NHS ENGLAND NEUROMUSCULAR DISORDERS AS PER BLUETEQ FORM AS PER BLUETEQ FORM AS PER BLUETEQ FORM √ √ 2001 AND LETTER NUMBER OF PATIENTS TREATED MICAFUNGIN FUNGAL INFECTION NHS ENGLAND ANTIFUNGALS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √ INDICATIONS WITHIN POLICY DRUGS USED IN METABOLIC MIGALASTAT FABRY'S DISEASE NHS ENGLAND NICE HST4 NICE NICE HIGHLY SPECIALISED DATABASE √ DISORDERS DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED MIGLUSTAT GAUCHER'S DISEASE/ NIEMANN-PICK NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √ DISORDERS CRITERIA ONLY CRITERIA ONLY MOMELOTINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ TA127 NATALIZUMAB MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NHS ENGLAND POLICY NHS ENGLAND POLICY NICE AUDIT √ √**** NHS ENGLAND POLICY: D04/P/b HIV IN COMBINATION WITH OTHER ANTI- NELFINAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √ RETROVIRAL DRUGS HIV IN COMBINATION WITH OTHER ANTI- NEVIRAPINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √ RETROVIRAL DRUGS NILOTINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA241, TA251, TA426 NICE NICE SACT √ √ NINTEDANIB OVARIAN CANCER NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL SACT √ NINTEDANIB (OFEV®) IDIOPATHIC PULMONARY FIBROSIS NHS ENGLAND IMMUNOMODULATING DRUGS TA 379 NICE NICE NICE AUDIT √ √ NINTEDANIB (VARGATEF®) NON-SMALL-CELL LUNG CANCER NHS ENGLAND IMMUNOMODULATING DRUGS TA347 NICE NICE SACT √ VIRAL HEPATITIS (B&C) & NITAZOXANIDE HEPATITIS C NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ RESPIRATORY SYNCYTIAL VIRUS DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED NITISINONE ALKAPTONURIA NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √ DISORDERS CRITERIA ONLY CRITERIA ONLY DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED NITISINONE TYROSINAEMIA NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √ DISORDERS CRITERIA ONLY CRITERIA ONLY VASODILATOR ANTIHYPERTENSIVE NITRIC OXIDE PULMONARY ARTERIAL HYPERTENSION NHS ENGLAND DRUGS/PULMANORY ARTERIAL AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √ HYPERTENSION

NUSINERSEN SPINAL MUSCULAR ATROPHY NHS ENGLAND NEURODEGENERATIVE CONDITIONS TA588 NICE NICE NICE AUDIT √ √

DRUGS USED IN METABOLIC OBETICHOLIC ACID PRIMARY BILIARY CIRRHOSIS NHS ENGLAND TA443 NICE NICE NICE AUDIT √ √ DISORDERS DRUGS AFFECTING THE IMMUNE OCRELIZUMAB MULTIPLE SCLEROSIS NHS ENGLAND TA 533, TA 585 NICE NICE NICE AUDIT √ √**** RESPONSE OCTOCOG ALFA HAEMOPHILIA A NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES: See also SSC 1818 AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

GROWTH HORMONE & GROWTH OCTREOLIN ACROMEGALY NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ HORMONE RECEPTOR ANTAGONIST

PRODUCT WITH LOWEST OCTREOTIDE CANCER NHS ENGLAND SOMATOSTATIN ANALOGUES AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √ PROCUREMENT COST TO BE USED

HIGHLY SPECIALISED HIGHLY SPECIALISED OCTREOTIDE CONGENITAL HYPERINSULINISM NHS ENGLAND SOMATOSTATIN ANALOGUES HIGHLY SPECIALISED CRITERIA ONLY √ CRITERIA ONLY CRITERIA ONLY

PRODUCT WITH LOWEST OCTREOTIDE*** ACROMEGALY NHS ENGLAND SOMATOSTATIN ANALOGUES AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √ PROCUREMENT COST TO BE USED

OLESOXIME SPINAL MUSCULAR ATROPHY NHS ENGLAND NEUROMUSCULAR DISORDERS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ LYSOSOMAL STORAGE DISORDER OLIPUDASE ALFA ACID SPHINGOMYELINASE DEFICIENCY NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ DRUGS OMALIZUMAB ASTHMA NHS ENGLAND ALLERGEN IMMUNOTHERAPY TA278 NICE NICE NICE AUDIT √ √ OMBITASVIR/PARITAPREVIR/RITON VIRAL HEPATITIS (B&C) & HEPATITIS C NHS ENGLAND TA 365 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √ √ AVIR + DASABUVIR + RIBAVIRIN RESPIRATORY SYNCYTIAL VIRUS OSILODROSTAT CUSHING'S DISEASE NHS ENGLAND OTHER ENDOCRINE DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ OZANIMOD MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ PACRITINIB MYELOFIBROSIS NHS ENGLAND PROTEIN KINASE INHIBITORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ FYBRODYSPLASIA OSSIFICANS DRUGS AFFECTING BONE PALOVAROTENE NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ PROGRESSIVA METABOLISM VIRAL HEPATITIS (B&C) & JCVI GUIDELINES PALIVIZUMAB RSV PROPHYLAXIS NHS ENGLAND AS PER SPECIFICATION AS PER SPECIFICATION √ √ RESPIRATORY SYNCYTIAL VIRUS PHE SPECIFICATION PARA-AMINOSALICYLIC ACID NHS ENGLAND CLINICAL MULTI DRUG RESITANT TB NHS ENGLAND ANTITUBERCULOSIS DRUGS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ COMMISSIONING POLICY: F04/P/a SPECIALIST ENDOCRINOLOGY PARATHYROID HORMONE NHS ENGLAND PARATHYROID HORMONE AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √ CONDITIONS PARENTERAL NUTRITION (HOME INTESTINAL FAILURE NHS ENGLAND PARENTERAL NUTRITION AS PER BLUETEQ FORM AS PER BLUETEQ FORM AS PER BLUETEQ FORM AUDIT √ √ USE)

ONLY WHEN DURATION OF PN IS > 14 DAYS OR INITIATED PRIOR TO PARENTERAL NUTRITION INTESTINAL FAILURE; INADEQUATE/ NHS ENGLAND PARENTERAL NUTRITION ADMISSION. ADULTS; SEE ALSO CG32. TRUST GUIDELINES TRUST GUIDELINES √ (INPATIENT USE) UNSAFE ENTERAL FEEDING SEE ALSO 'MANUAL FOR PRESCRIBED SPECIALISED SERVICES'

PARICALCITOL HYPERPARATHYROIDISM NHS ENGLAND OTHER ENDOCRINE DRUGS AS PER CINACALCET AS PER CINACALCET AS PER CINACALCET AS PER CINACALCET √ VIRAL HEPATITIS (B&C) & PARITAPREVIR HEPATITIS C NHS ENGLAND NICE TA 499 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √ RESPIRATORY SYNCYTIAL VIRUS NOT ROUTINELY COMMISSIONED PASIREOTIDE ACROMEGALY NHS ENGLAND SOMATOSTATIN ANALOGUES AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ NHS ENGLAND POLICY 16003/P NHS ENGLAND CLINICAL PASIREOTIDE CUSHING'S DISEASE NHS ENGLAND SOMATOSTATIN ANALOGUES NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √ COMMISSIONING POLICY: A03X03/01 PATISIRAN AMYLOIDOSIS NHS ENGLAND NOVEL - NO GROUP NAME AGREED HST10 NICE NICE NICE AUDIT √ √ TA215 PAZOPANIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS NOT ROUTINELY COMMISSIONED NHS NICE NICE SACT √ ENGLAND POLICY STATEMENT 170117P

NHS England drugs-list v15 2020-2021.xlsx NHSE Commissioned PbRE Drugv15 7 31/03/2020 SUITABLE FOR SUITABLE FOR SPECIALIST SHARED CARE SHARED CARE CENTRE ONLY BETWEEN PRIOR WITH PRIMARY (includng SPECIALIST APPROVAL CARE (IF DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA STOPPING CRITERIA MONITORING/AUDIT REQUIREMENTS outreach when AND PROFORMA SUPPORTED BY delivered as part SECONDARY REQUIRED LOCAL of a provider CARE VIA PRESCRIBING network) NETWORK COMMITTEE) MODEL NHS ENGLAND CLINICAL VIRAL HEPATITIS (B&C) & COMMISSIONING POLICY: B07/P/a; TA75, PEG INTERFERON ALFA HEPATITIS B AND C NHS ENGLAND NICE NICE NICE AUDIT √ RESPIRATORY SYNCYTIAL VIRUS TA96, TA106, TA200, TA 300 CG165

ROUTINELY COMMISSIONED AS PER PEGINTERFERON BETA-1A MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS SSC1534: MULTIPLE SCLEROSIS FIRST NHS ENGLAND POLICY NHS ENGLAND POLICY NICE AUDIT √ √**** LINE DISEASE MODIFYING AGENTS

LYSOSOMAL STORAGE DISORDER PEGUNIGALSIDASE ALFA FABRY'S DISEASE NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ DRUGS DRUGS USED IN METABOLIC PEGVALIASE PHENYLKETONURIA NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ DISORDERS

HYPOTHALMIC & ANTERIOR PITUITARY NHS ENGLAND CLINICAL PEGVISOMANT ACROMEGALY NHS ENGLAND NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ HORMONES & ANTI-OESTROGENS COMMISSIONING POLICY: 16050/P

TA 357, TA366, TA428, TA531 CDF POLICY (TA 447 (replaced by TA531), NICE NICE PEMBROLIZUMAB CANCER INDICATIONS NHS ENGLAND/CDF CANCER EXCLUSION SACT √ √ TA 519, TA522 TA540, TA553, TA557 & CDF CDF TA600) NHS ENGLAND CLINICAL DRUG RESISTANT GESTATIONAL PEMBROLIZUMAB NHS ENGLAND CANCER EXCLUSION COMMISSIONING POLICY STATEMENT: NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ TROPHOBLASTIC NEOPLASIA 170027P VIRAL HEPATITIS (B&C) & PIBRENTASVIR HEPATITIS C NHS ENGLAND TA499 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √ RESPIRATORY SYNCYTIAL VIRUS PIRFENIDONE IDIOPATHIC PULMONARY FIBROSIS NHS ENGLAND PULMONARY FIBROSIS TA 504 (SPECIALIST CENTRE ONLY) NICE NICE NICE AUDIT √ √ NUMBER OF PATIENTS TREATED NHS ENGLAND CLINICAL DRUGS AFFECTING THE IMMUNE NUMBER OF PATIENTS PLERIXAFOR STEM CELL MOBILISATION NHS ENGLAND COMMISSIONING POLICY: B04/P/b, NHS ENGLAND POLICY NHS ENGLAND POLICY √ √ RESPONSE SUCCESSFULLY TRANSPLANTED 16064/P STAGE DRUG UTILISED POMALIDOMIDE CANCER NHS ENGLAND IMMUNOMODULATING DRUGS TA427 NICE NICE SACT √ √ POMALIDOMIDE MYELOFIBROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ PONATINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA451 NICE NICE SACT √ √ DRUGS USED FOR NEUROMUSCULAR PONESIMOD MULTIPLE SCLEROSIS NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ DISORDERS NUMBER OF PATIENTS TREATED POSACONAZOLE FUNGAL INFECTION NHS ENGLAND ANTIFUNGALS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √ INDICATIONS WITHIN POLICY PRETOMANID MULTI DRUG RESITANT TB NHS ENGLAND ANTITUBERCULOSIS DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ AS PER BCSH GUIDELINES FOR PROTEIN C NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES PRODUCTS ON CMU FRAMEWORK √ SPECIALISED INDICATIONS AS PER BCSH GUIDELINES FOR PROTHROMBIN COMPLEX NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES BCSH GUIDELINES PRODUCTS ON CMU FRAMEWORK √ SPECIALISED INDICATIONS HIV IN COMBINATION WITH OTHER ANTI- RALTEGRAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √ RETROVIRAL DRUGS GOUT AND CYTOTOXIC-INDUCED RASBURICASE HYPERURICAEMIA NHS ENGLAND AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √ HYPERURICAEMIA PAROXYSMAL NOCTURNAL PAROXYSMAL NOCTURNAL RAVULIZUMAB NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ HAEMOGLOBINURIA HAEMOGLOBINURIA RAXIBACUMAB INHALED ANTHRAX NHS ENGLAND NOVEL - NO GROUP NAME AGREED NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ PREVENTION OF DELAYED GRAFT REFANALIN NHS ENGLAND NOVEL - NO GROUP NAME AGREED NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ FUNCTION REGORAFENIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA488 & TA555 NICE NICE SACT √ √ PREVENTION OF DELAYED GRAFT REPARIXIN NHS ENGLAND NOVEL - NO GROUP NAME AGREED NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ FUNCTION RESLIZUMAB ASTHMA NHS ENGLAND ALLERGEN IMMUNOTHERAPY TA479 NICE NICE NICE AUDIT √ √ LYSOSOMAL STORAGE DISORDER REVEGLUCOSIDASE ALFA POMPE DISEASE NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ DRUGS

RISDIPLAM SPINAL MUSCULAR ATROPHY NHS ENGLAND NEURODEGENERATIVE CONDITIONS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

RIGOSERTIB MDS/PANCREATIC CANCER NHS ENGLAND MYELODYSPLASTIC SYNDROME NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ HIV IN COMBINATION WITH OTHER ANTI- RILPIVIRINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √ RETROVIRAL DRUGS

RIMEPORIDE DUCHENNE MUSCULAR DYSTROPHY NHS ENGLAND NEUROMUSCULAR DISORDERS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

VASODILATOR ANTIHYPERTENSIVE PULMONARY ARTERIAL HYPERTENSION NHS ENGLAND CLINICAL RIOCIGUAT NHS ENGLAND DRUGS/PULMANORY ARTERIAL NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ (CTEPH) COMMISSIONING POLICY: A11/P/c HYPERTENSION VASODILATOR ANTIHYPERTENSIVE NHS ENGLAND CLINICAL RIOCIGUAT PULMONARY ARTERIAL HYPERTENSION NHS ENGLAND DRUGS/PULMANORY ARTERIAL NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ COMMISSIONING POLICY: 16055/P HYPERTENSION HIV IN COMBINATION WITH OTHER ANTI- RITONAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √ RETROVIRAL DRUGS STEROID SENSITIVE NEPHROTIC NHS ENGLAND CLINICAL RITUXIMAB NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ SYNDROME COMMISSIONING POLICY: E03/P/b STEROID RESISTANT NEPHROTIC NHS ENGLAND CLINICAL RITUXIMAB NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ SYNDROME COMMISSIONING POLICY: E03/P/c NOT ROUTINELY COMMISSIONED RITUXIMAB PRIMARY SJOGREN'S SYNDROME (PSS) NHS ENGLAND CYTOKINE MODULATORS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ NHS ENGLAND POLICY 16048/P CHRONIC INFLAMMATORY NOT ROUTINELY COMMISSIONED RITUXIMAB NHS ENGLAND CYTOKINE MODULATORS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ DEMYELINATING POLYNEUROPATHY NHS ENGLAND POLICY 170026/P NHS ENGLAND CLINICAL RITUXIMAB JUVENILE ARTHRITIS-PAEDIATRIC NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √ COMMISSIONING POLICY: E03/P/d NHS ENGLAND CLINICAL RITUXIMAB ACQUIRED HAEMOPHILIA NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ COMMISSIONING POLICY: F02/P/a TA308 NICE/ NHS ENGLAND NICE/ NHS ENGLAND RITUXIMAB ANCA-POSITIVE VASCULITIS NHS ENGLAND CYTOKINE MODULATORS NICE/ NHS ENGLAND POLICY √ √ NHS ENGLAND POLICY: A13/P/a POLICY POLICY ANTI-NMDAR AUTOIMMUNE NHS ENGLAND CLINICAL RITUXIMAB NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √ ENCEPHALITIS COMMISSIONING POLICY:16036/P CONNECTIVE TISSUE DISEASE - NOT ROUTINELY COMMISSIONED RITUXIMAB NHS ENGLAND CYTOKINE MODULATORS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ INTERSTITIAL LUNG DISEASE NHS ENGLAND POLICY 170015/P CYTOPENIA COMPLICATING PRIMARY NHS ENGLAND CLINICAL RITUXIMAB NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ IMMUNODEFICIENCY COMMISSIONING POLICY:16044/P CHRONIC GRAFT VERSUS HOST NHS ENGLAND CLINICAL RITUXIMAB NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ DISEASE COMMISSIONING POLICY:16069/P NHS ENGLAND CLINICAL RITUXIMAB SLE NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √ COMMISSIONING POLICY: A13/PS/a NOT ROUTINELY COMMISSIONED RITUXIMAB MEMBRANOUS NEPHROPATHY NHS ENGLAND CYTOKINE MODULATORS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ NHS ENGLAND POLICY 16047/P DERMATOMYOSITIS AND POLYMYOSITIS NHS ENGLAND CLINICAL RITUXIMAB NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √ (ADULTS) COMMISSIONING POLICY:16036/P RITUXIMAB NEUROMYELITIS OPTICA NHS ENGLAND CYTOKINE MODULATORS AS PER SPECIFICATION AS PER SPECIFICATION AS PER SPECIFICATION AS PER SPECIFICATION √

NHS England drugs-list v15 2020-2021.xlsx NHSE Commissioned PbRE Drugv15 8 31/03/2020 SUITABLE FOR SUITABLE FOR SPECIALIST SHARED CARE SHARED CARE CENTRE ONLY BETWEEN PRIOR WITH PRIMARY (includng SPECIALIST APPROVAL CARE (IF DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA STOPPING CRITERIA MONITORING/AUDIT REQUIREMENTS outreach when AND PROFORMA SUPPORTED BY delivered as part SECONDARY REQUIRED LOCAL of a provider CARE VIA PRESCRIBING network) NETWORK COMMITTEE) MODEL ABO-INCOMPATIBLE KIDNEY RITUXIMAB NHS ENGLAND CYTOKINE MODULATORS AS PER SPECIFICATION AS PER SPECIFICATION AS PER SPECIFICATION AS PER SPECIFICATION √ TRANSPLANTS PEMPHIGUS VULGARIS AND NHS ENGLAND CLINICAL RITUXIMAB NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ PEMPHIGOID DISEASE COMMISSIONING POLICY:16035/P NHS ENGLAND CLINICAL RITUXIMAB IMMUNOGLOBIN G4 RELATED DISEASE NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ COMMISSIONING POLICY:16057/P NHS ENGLAND CLINICAL RITUXIMAB MYASTHENIA GRAVIS NHS ENGLAND CYTOKINE MODULATORS COMMISSIONING POLICY STATEMENT NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √ 170084P

FOCAL SEGMENTAL NOT ROUTINELY COMMISSIONED RITUXIMAB NHS ENGLAND CYTOKINE MODULATORS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ GLOMERULOSCLEROSIS NHS ENGLAND POLICY STATEMENT 1818

TA65, TA137, TA174, TA193, TA65, TA137, TA174, TA193, TA65, TA137, TA174, TA193, TA226, TA243 RITUXIMAB IV CANCER NHS ENGLAND CYTOKINE MODULATORS TA226, TA243 TA226, TA243 SACT √ NHS ENGLAND CDF LETTER NHS ENGLAND CDF LETTER NHS ENGLAND CDF LETTER

AS PER CIRCULAR IE ONLY RITUXIMAB SUBCUTANEOUS CANCER NHS ENGLAND CYTOKINE MODULATORS COMMISSIONED FOR FOLLICULAR AS PER CIRCULAR AS PER CIRCULAR SACT √ FORMULATION LYMPHOMA MAINTENANCE TREATMENT

RIVIPANSEL SODIUM HEPATIC VENO-OCCLUSIVE DISEASE NHS ENGLAND NOVEL - NO GROUP NAME AGREED NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

RIVIPANSEL SODIUM SICKLE CELL DISEASE NHS ENGLAND NOVEL - NO GROUP NAME AGREED NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ ROMIPLOSTIM ITP IN CHILDREN NHS ENGLAND PLATELET DISORDER DRUGS AS PER ADULT TA 221 NICE NICE NICE AUDIT √ √ VIRAL HEPATITIS (B&C) & ROPEGINTERFERON ALFA-2b HEPATITIS C NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ RESPIRATORY SYNCYTIAL VIRUS

DRUGS USED IN HYPOPLASTIC, ROXADUSTAT DIALYSIS-INDUCED ANAEMIA NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ HAEMOLYTIC, AND RENAL ANAEMIAS

RURIOCTOCOG ALFA PEGOL HAEMOPHILIA A NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ VIRAL HEPATITIS (B&C) & RUZASVIR HEPATITIS C NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ RESPIRATORY SYNCYTIAL VIRUS RUXOLITINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA 386 NICE NICE SACT √ CONGENITAL SUCRASE ISOMALTASE DRUGS USED IN METABOLIC SACROSIDASE NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ DEFICIENCY DISORDERS NOT ROUTINELY COMMISSIONED ADULTS AND CHILDREN WITH DRUGS USED IN METABOLIC SAPROPTERIN NHS ENGLAND (NHS ENGLAND CLINICAL AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ PHENYLKETONURIA DISORDERS COMMISSIONING POLICY: 170103P) DRUGS USED IN METABOLIC NHS ENGLAND CLINICAL SAPROPTERIN MATERNAL PHENYLKETONURIA NHS ENGLAND NHS ENGLAND POLICY NHS ENGLAND POLICY HIGHLY SPECIALISED DATABASE √ DISORDERS COMMISSIONING POLICY: E12/P/a HIV IN COMBINATION WITH OTHER ANTI- SAQUINAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √ RETROVIRAL DRUGS SATRALIZUMAB NEUROMYELITIS OPTICA NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ DRUGS USED IN METABOLIC NOT ROUTINELY COMMISSIONED SEBELIPASE ALFA LYSOSOMAL ACID LIPASE DEFICIENCY NHS ENGLAND AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ DISORDERS NICE HST IN PROGRESS VASODILATOR ANTIHYPERTENSIVE NHS ENGLAND CLINICAL SELEXIPAG PULMONARY ARTERIAL HYPERTENSION NHS ENGLAND DRUGS/PULMANORY ARTERIAL NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ COMMISSIONING POLICY: 170104P HYPERTENSION

DRUGS AFFECTING BONE SETRUSUMAB OSTEOGENESIS IMPERFECTA NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ METABOLISM

SEVELAMER ADULT RENAL DIALYSIS ONLY NHS ENGLAND PHOSPHATE BINDING AGENTS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √ SIPONIMOD MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ TA481, TA482 TRANSPLANT IMMUNOSUPPRESSION DRUGS AFFECTING THE IMMUNE PRODUCT WITH LOWEST SIROLIMUS (RAPAMUNE) NHS ENGLAND NEW PATIENTS ONLY UNTIL FORMAL NICE NICE √* √* ONLY RESPONSE PROCUREMENT COST TO BE USED REPATRIATION AGREED NARCOLEPSY - PEADIATRIC SERVICES NHS ENGLAND CLINICAL SODIUM OXYBATE NHS ENGLAND HYPNOTICS & ANXIOLYTICS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √ ONLY COMMISSIONING POLICY: 16065/P DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED SODIUM PHENYLBUTYRATE UREA CYCLE DISORDERS NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √ DISORDERS CRITERIA ONLY CRITERIA ONLY SOFOSBUVIR/LEDIPASVIR +/- VIRAL HEPATITIS (B&C) & HEPATITIS C NHS ENGLAND TA 363 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √ √ RIBAVIRIN RESPIRATORY SYNCYTIAL VIRUS SOFOSBUVIR/PEGINTERFERON+ VIRAL HEPATITIS (B&C) & HEPATITIS C NHS ENGLAND TA 330 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √ √ RIBAVIRIN RESPIRATORY SYNCYTIAL VIRUS VIRAL HEPATITIS (B&C) & SOFOSBUVIR/VELPATASVIR HEPATITIS C NHS ENGLAND TA 430 AS PER RUN RATE CARD AS PER RUN RATE CARD HEPATITIS C MDS √ √ RESPIRATORY SYNCYTIAL VIRUS SORAFENIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA 474 & TA 535 NICE NICE SACT √ √ HIV IN COMBINATION WITH OTHER ANTI- STAVUDINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √ RETROVIRAL DRUGS CLINICAL GUIDELINES FOR IMMUNOGLOBULIN USE, SECOND QUALITY DASHBOARD SUBCUTANEOUS HUMAN NORMAL INTRAVENOUS/SUBCUTANEOUS EDITION UPDATE (JULY 2011) MULTIPLE INDICATIONS NHS ENGLAND NATIONAL GUIDELINES NATIONAL GUIDELINES NATIONAL IMMUNOGLOBULIN DATA √ IMMUNOGLOBULINS HUMAN NORMAL IMMUNOGLOBULINS IMMUNOGLOBULIN GUIDELINES BASE PUBLISHED 2019 ON MDSAS WEBSITE

SUCROFERRIC OXYHDROXIDE ADULT RENAL DIALYSIS ONLY NHS ENGLAND PHOSPHATE BINDING AGENTS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √

SUNITINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA169, TA179, TA449 NICE NICE SACT √ (Only TA449) √ SUTIMLIMAB PRIMARY COLD AGGLUTININ DISEASE NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ TABALUMAB SLE NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

TAFAMIDIS AMYLOIDOSIS NHS ENGLAND NEURODEGENERATIVE CONDITIONS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED TALIGLUCERASE ALFA GAUCHER'S DISEASE NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √ DISORDERS CRITERIA ONLY CRITERIA ONLY VIRAL HEPATITIS (B&C) & TARIBAVIRIN HEPATITIS C NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ RESPIRATORY SYNCYTIAL VIRUS TEDUGLUTIDE SHORT BOWEL SYNDROME NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ VIRAL HEPATITIS (B&C) & NOT ROUTINELY COMMISSIONED TELBIVUDINE HEPATITIS B NHS ENGLAND AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ RESPIRATORY SYNCYTIAL VIRUS (TA154) NOT ROUTINELY COMMISSIONED TEMSIROLIMUS CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS IFR IFR SACT √ (TA178) HIV IN COMBINATION WITH OTHER ANTI- RETROVIRAL DRUGS TA173 (FOR HEPATITIS B)/AGREED BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) TENOFOVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS HARS DATASET √ HEPATITIS B +/- OTHER ANTI- REGIONAL GUIDELINES FOR HIV NICE NICE RETROVIRAL DRUGS TENOFOVIR ALAFENAMIDE HEPATITIS B NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ HIV IN COMBINATION WITH OTHER ANTI- NHS ENGLAND CLINICAL TENOFOVIR ALAFENAMIDE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NHS ENGLAND POLICY NHS ENGLAND POLICY HARS DATASET √ RETROVIRAL DRUGS COMMISSIONING POLICY: 16043/P TENOFOVIR ALAFENAMIDE + HIV IN COMBINATION WITH OTHER ANTI- NHS ENGLAND CLINICAL COBICISTAT + ELVITEGRAVIR + NHS ENGLAND AIDS/HIV ANTIRETROVIRALS NHS ENGLAND POLICY NHS ENGLAND POLICY HARS DATASET √ RETROVIRAL DRUGS COMMISSIONING POLICY: 16043/P EMTRICITABINE

NHS England drugs-list v15 2020-2021.xlsx NHSE Commissioned PbRE Drugv15 9 31/03/2020 SUITABLE FOR SUITABLE FOR SPECIALIST SHARED CARE SHARED CARE CENTRE ONLY BETWEEN PRIOR WITH PRIMARY (includng SPECIALIST APPROVAL CARE (IF DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA STOPPING CRITERIA MONITORING/AUDIT REQUIREMENTS outreach when AND PROFORMA SUPPORTED BY delivered as part SECONDARY REQUIRED LOCAL of a provider CARE VIA PRESCRIBING network) NETWORK COMMITTEE) MODEL

TENOFOVIR DISOPROXIL + NHS ENGLAND CLINICAL HIV IN COMBINATION WITH OTHER ANTI- COBICISTAT + ELVITEGRAVIR + NHS ENGLAND AIDS/HIV ANTIRETROVIRALS COMMISSIONING POLICY: NHS ENGLAND POLICY NHS ENGLAND POLICY HARS DATASET √ RETROVIRAL DRUGS EMTRICITABINE F03/P/b/AGREED REGIONAL GUIDELINES

TENOFOVIR + EMTRICITABINE + HIV IN COMBINATION WITH OTHER ANTI- NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √ EFAVIRENZ RETROVIRAL DRUGS TENOFOVIR + EMTRICITABINE + HIV IN COMBINATION WITH OTHER ANTI- NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √ RILPIVIRINE RETROVIRAL DRUGS PREVENTION OF DELAYED GRAFT TEPRASIRAN NHS ENGLAND RENAL TRANSPLANTATION NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ FUNCTION

TEPROTUMUMAB GRAVES ORBITOPATHY NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

TA303 TERIFLUNOMIDE MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NICE NICE NICE AUDIT √ √**** NHS ENGLAND POLICY: D04/P/b DRUGS AFFECTING BONE NOT ROUTINELY COMMISSIONED TERIPARATIDE OSTEOGENESIS IMPERFECTA NHS ENGLAND AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ METABOLISM NHS ENGLAND POLICY: 16002/P NHS ENGLAND CLINICAL DRUGS AFFECTING BONE TERIPARATIDE MALE AND JUVENILE OSTEOPOROSIS NHS ENGLAND COMMISSIONING POLICY STATEMENT NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ METABOLISM 170064P DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED TETRAHYDROBIOPTERIN PHENYLKETONURIA NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √ DISORDERS CRITERIA ONLY CRITERIA ONLY NHS ENGLAND URGENT POLICY TEZACAFTOR WITH IVACAFTOR CYSTIC FIBROSIS NHS ENGLAND MUCOLYTICS NHS ENGLAND POLICY NHS ENGLAND POLICY AS PER POLICY √ STATEMENT 190137P TEZEPELUMAB ASTHMA NHS ENGLAND ALLERGEN IMMUNOTHERAPY NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ THALIDOMIDE CANCER NHS ENGLAND IMMUNOMODULATING DRUGS TA228 NICE NICE SACT √

THROMBOMODULIN, PSEUDOANEURYSM NHS ENGLAND BLOOD-RELATED PRODUCTS IPG060 IPG060 NICE √ RECOMBINANT HUMAN

HIV IN COMBINATION WITH OTHER ANTI- TIPRANAVIR NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √ RETROVIRAL DRUGS NHS ENGLAND CLINICAL NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY TOBRAMYCIN CYSTIC FIBROSIS NHS ENGLAND ANTIBACTERIAL DRUGS COMMISSIONING POLICY: A01/P/b √* √* NICE NICE NICE AUDIT TA276 NHS ENGLAND CLINICAL TOCILIZUMAB ADULT ONSET STILLS DISEASE NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √ COMMISSIONING POLICY 170056P

NHS ENGLAND CLINICAL TOCILIZUMAB JUVENILE ARTHRITIS-PAEDIATRIC NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √ COMMISSIONING POLICY: E03/P/d; TA 373

NHS ENGLAND CLINICAL TOCILIZUMAB TAKAYASU ARTERITIS NHS ENGLAND CYTOKINE MODULATORS NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ COMMISSIONING POLICY 16056/P TOCILIZUMAB GIANT CELL ARTERITIS NHS ENGLAND CYTOKINE MODULATORS TA 518 NICE NICE NICE AUDIT √ √ TOCILIZUMAB CYTOKINE RELEASE SYNDROME NHS ENGLAND CYTOKINE MODULATORS AS PER BLUETEQ FORM AS PER BLUETEQ FORM AS PER BLUETEQ FORM BLUETEQ AUDIT √ √ POSTERIOR PITUITARY HORMONES NHS ENGLAND CLINICAL TOLVAPTAN HYPONATRAEMIA IN CANCER NHS ENGLAND NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ AND ANTAGONISTS COMMISSIONING POLICY 16051/P TRALOKINUMAB ASTHMA NHS ENGLAND ALLERGEN IMMUNOTHERAPY NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ TRENONACOG ALPHA HAEMOPHILIA B NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ DRUGS USED IN METABOLIC NHS ENGLAND CLINICAL TRIENTENE WILSONS DISEASE NHS ENGLAND NHS ENGLAND POLICY NHS ENGLAND POLICY NHS ENGLAND POLICY √ √ DISORDERS COMMISSIONING POLICY 170094P DRUGS USED IN METABOLIC TRIHEPTANOIN PYRUVATE CARBOXYLASE DEFICIENCY NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ DISORDERS VIRAL HEPATITIS (B&C) & UPRIFOSBUVIR HEPATITIS C NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ RESPIRATORY SYNCYTIAL VIRUS

USTEKINUMAB PLAQUE PSORIASIS IN CHILDREN NHS ENGLAND CYTOKINE MODULATORS TA455 NICE NICE NICE AUDIT √ √

DRUGS USED IN HYPOPLASTIC, VADADUSTAT DIALYSIS-INDUCED ANAEMIA NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ HAEMOLYTIC, AND RENAL ANAEMIAS

NUMBER OF PATIENTS TREATED VALGANCICLOVIR CYTOMEGALOVIRUS NHS ENGLAND CYTOMEGALOVIRUS INFECTION AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √ INDICATIONS WITHIN POLICY NOT ROUTINELY COMMISSIONED VANDETANIB THYROID CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS IFR IFR SACT √ (TA550) VATIQUINONE FRIEDREICHS ATAXIA NHS ENGLAND NEURODEGENERATIVE CONDITIONS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √

DRUGS USED IN METABOLIC HIGHLY SPECIALISED HIGHLY SPECIALISED VELAGLUCERASE ALFA GAUCHER'S DISEASE NHS ENGLAND NHS ENGLAND SERVICE SPECIFICATION HIGHLY SPECIALISED DATABASE √ DISORDERS CRITERIA ONLY CRITERIA ONLY

DRUGS AFFECTING BONE VELCALCETIDE HYPERPARATHYROIDISM NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ METABOLISM DRUGS USED TO TREAT ALPHA VELMANASE ALFA ALPHA MANNOSIDASE DEFICIENCY NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ MANNOSIDOSIS VEMURAFENIB MELANOMA NHS ENGLAND PROTEIN KINASE INHIBITORS TA269 NICE NICE NICE AUDIT √ LYSOSOMAL STORAGE DISORDER VESTRONIDASE ALFA MUCOPOLYSACCHARIDOSIS VII NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ DRUGS FAMILIAL CHYLOMICRONEMIA VOLANESORSEN NHS ENGLAND LIPID-REGULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ SYNDROME VONICOG ALFA VON WILLEBRAND DEFICIENCY NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ VON WILLEBRAND FACTOR, VON WILLEBRAND DEFICIENCY NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ RECOMBINANT

RETINAL DISORDERS/INTRAOCULAR VORETIGENE NEPARVOVEC INHERITED RETINAL DYSTROPHIES NHS ENGLAND HST11 NICE NICE NICE AUDIT √ √ LENS REPLACEMENT SURGERY

NUMBER OF PATIENTS TREATED VORICONAZOLE FUNGAL INFECTION NHS ENGLAND ANTIFUNGALS AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES PROPORTION GIVEN FOR SPC √ INDICATIONS WITHIN POLICY HIGHLY SPECIALISED HIGHLY SPECIALISED VORICONAZOLE CHRONIC PULMONARY ASPERGILLOSIS NHS ENGLAND ANTIFUNGALS HIGHLY SPECIALISED CRITERIA ONLY √ CRITERIA ONLY CRITERIA ONLY VOXELOTOR SICKLE CELL DISEASE NHS ENGLAND NOVEL - NO GROUP NAME AGREED NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ VX-210 SPINAL CORD INJURY NHS ENGLAND NOVEL - NO GROUP NAME AGREED NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ NOT ROUTINELY COMMISSIONED - NHS ZICONOTIDE INTRATHECAL ANALGESIA NHS ENGLAND NON-OPIOID ANALGESICS AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ ENGLAND POLICY 16011/P HIV IN COMBINATION WITH OTHER ANTI- ZIDOVUDINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √ RETROVIRAL DRUGS HIV IN COMBINATION WITH OTHER ANTI- ZIDOVUDINE + LAMIVUDINE NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √ RETROVIRAL DRUGS ZIDOVUDINE + LAMIVUDINE + HIV IN COMBINATION WITH OTHER ANTI- NHS ENGLAND AIDS/HIV ANTIRETROVIRALS AGREED REGIONALGUIDELINES BHIVA GUIDELINES (8) BHIVA GUIDELINES (8) HARS DATASET √ ABACAVIR RETROVIRAL DRUGS OTHER DRUGS NOT LISTED UNDER PBR EXCLUSIONS LAMBERT EATON MYASTHENIC 3,4 DIAMINOPYRIDINE NHS ENGLAND AGREED TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √ SYNDROME

NHS England drugs-list v15 2020-2021.xlsx NHSE Commissioned PbRE Drugv15 10 31/03/2020 SUITABLE FOR SUITABLE FOR SPECIALIST SHARED CARE SHARED CARE CENTRE ONLY BETWEEN PRIOR WITH PRIMARY (includng SPECIALIST APPROVAL CARE (IF DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA STOPPING CRITERIA MONITORING/AUDIT REQUIREMENTS outreach when AND PROFORMA SUPPORTED BY delivered as part SECONDARY REQUIRED LOCAL of a provider CARE VIA PRESCRIBING network) NETWORK COMMITTEE) MODEL TA563 NICE NICE ABEMACICLIB CANCER CDF CANCER EXCLUSION SACT √ √ CDF TA579 CDF CDF

ALBUMIN BOUND PACLITAXEL CANCER NHS ENGLAND CANCER EXCLUSION TA 476 NICE NICE SACT √ √

ALECTINIB CANCER NHS ENGLAND CANCER EXCLUSION TA 536 NICE NICE SACT √ √

TA 526 NOT ROUTINELY COMMISSIONED ARSENIC TRIOXIDE CANCER NHS ENGLAND CANCER EXCLUSION NICE NICE SACT √ √ NHS ENGLAND POLICY STATEMENT 170072P

NHS ENGLAND/ TA520, TA525, TA584 NICE NICE ATEZOLIZUMAB CANCER CANCER EXCLUSION SACT √ √ CDF CDF (TA 492) CDF CDF AUTOLOGOUS CHONDROCYTE ARTICULAR CARTILAGE DEFECT NHS ENGLAND TA 477 & TA 508 NICE NICE NICE AUDIT √ √ IMPLANTATION

TA 517 NICE NICE AVELUMAB CANCER NHS ENGLAND CANCER EXCLUSION SACT √ √ CDF CDF CDF

AXICABTAGENE CILOLEUCEL CANCER CDF ATMP TA 559 CDF CDF SACT √ √ TRANSPLANT IMMUNOSUPPRESSION NEW PATIENTS ONLY UNTIL FORMAL AZATHIOPRINE NHS ENGLAND TRUST GUIDELINES TRUST GUIDELINES √* √* ONLY REPATRIATION AGREED

TA216 NICE NICE NHS ENGLAND/ CDF POLICY √ (Not for all BENDAMUSTINE CANCER CANCER EXCLUSION CDF CDF SACT √ CDF NHS ENGLAND POLICY (WITH NHS ENGLAND POLICY NHS ENGLAND POLICY policies) RITUXIMAB) 170055P, 17088P & 170054P

BINIMETINIB CANCER NHS ENGLAND CANCER EXCLUSION TA562 NICE NICE SACT √ √

BLINATUMOMAB CANCER NHS ENGLAND CANCER EXCLUSION TA450, TA589 NICE NICE SACT √ √ TA446 (replaced by TA524), TA478, TA524, BRENTUXIMAB CANCER NHS ENGLAND CANCER EXCLUSION NICE NICE SACT √ √ TA577

BRIGATINIB CANCER NHS ENGLAND CANCER EXCLUSION TA571 NICE NICE SACT √ √

CABAZITAXEL CANCER NHS ENGLAND CANCER EXCLUSION TA 391 NICE NICE SACT √ √

CABOZANTINIB CANCER NHS ENGLAND/CDF CANCER EXCLUSION TA 463, TA516 & TA 542 NICE NICE SACT √ √

CARFILZOMIB CANCER NHS ENGLAND CANCER EXCLUSION TA 457 NICE NICE SACT √ √ CEMIPLIMAB CANCER CDF CANCER EXCLUSION TA 592 (CDF) CDF CDF SACT √ √ CERITINIB CANCER NHS ENGLAND CANCER EXCLUSION TA 395, TA 500 NICE NICE SACT √ √ NHS ENGLAND/ TRUST GUIDELINES/ NICE/ TRUST GUIDELINES/ NICE/ CHEMOTHERAPY CANCER - (NOT SPECIFICALLY LISTED) CANCER EXCLUSION TRUST GUIDELINES/ NICE/ CDF POLICY SACT √ CDF CDF POLICY CDF POLICY

TRANSPLANT IMMUNOSUPPRESSION NEW PATIENTS ONLY UNTIL FORMAL PRODUCT WITH LOWEST CICLOSPORIN NHS ENGLAND TRUST GUIDELINES TRUST GUIDELINES √* √* ONLY REPATRIATION AGREED PROCUREMENT COST TO BE USED

CDF POLICY CLOFARABINE CANCER CDF CANCER EXCLUSION NOT ROUTINELY COMMISSIONED - NHS CDF CDF SACT √ ENGLAND POLICY 170080P DRUGS FOR MINERAL BONE COLESTILAN ADULT RENAL DIALYSIS ONLY NHS ENGLAND TRUST GUIDELINES TRUST GUIDELINES TRUST GUIDELINES √ DISORDERS

DACOMITINIB CANCER NHS ENGLAND CANCER EXCLUSION TA595 NICE NICE SACT √ √

DARATUMUMAB CANCER CDF CANCER EXCLUSION CDF (TA 510, TA 573) CDF CDF SACT √ √ DINUTUXIMAB CANCER NHS ENGLAND CANCER EXCLUSION TA 538 NICE NICE SACT √ √ NHS ENGLAND CLINICAL DOCETAXEL CANCER NHS ENGLAND CANCER EXCLUSION COMMISSIONING POLICY STATEMENT NHS ENGLAND POLICY NHS ENGLAND POLICY SACT √ B15/PS/a

DURVALUMAB CANCER CDF CANCER EXCLUSION CDF TA578 CDF CDF SACT √ √

ENCORAFENIB CANCER NHS ENGLAND CANCER EXCLUSION TA562 NICE NICE SACT √ √

ERIBULIN CANCER NHS ENGLAND CANCER EXCLUSION NICE TA 423 NICE NICE SACT √ √

FACTOR X (COAGADEX) HEREDITARY FACTOR X DEFICIENCY NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ GEMCITABINE (WITH CANCER NHS ENGLAND CANCER EXCLUSION NHS ENGLAND POLICY 170101P NHS ENGLAND POLICY NHS ENGLAND POLICY SACT √ √ CAPECITABINE) GEMTUZUMAB OZOGAMICIN CANCER NHS ENGLAND CANCER EXCLUSION TA 545 NICE NICE SACT √ √ TA429, TA502 NICE NICE IBRUTINIB CANCER NHS ENGLAND/CDF PROTEIN KINASE INHIBITORS SACT √ √ CDF (TA491) CDF CDF IDELALISIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS NICE TA 359 NICE NICE SACT √ INOTUZUMAB OZOGAMICIN CANCER NHS ENGLAND CANCER EXCLUSION TA 541 NICE NICE SACT √ √ NICE NICE IPILIMUMAB CANCER NHS ENGLAND/CDF CANCER EXCLUSION TA268, TA319, TA400, CDF TA581 SACT √ √ CDF CDF LENVATINIB CANCER NHS ENGLAND PROTEIN KINASE INHIBITORS TA498, TA 535 & TA 551 NICE NICE SACT √ √ LIPOSOMAL CYTARABINE- CANCER NHS ENGLAND CANCER EXCLUSION TA 522 NICE NICE SACT √ √ DAUNORUBICIN LUTETIUM (177Lu) CANCER NHS ENGLAND CANCER EXCLUSION TA 539 NICE NICE SACT √ √ OXODOTREOTIDE MESENCHYMAL STEM CELLS (E.G. ACUTE GVHD AND OTHER INDICATIONS NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ PROCHYMAL®) (BCSH) MIDOSTAURIN CANCER NHS ENGLAND CANCER EXCLUSION TA 523 NICE NICE SACT √ √ TA481, TA482 TRANSPLANT IMMUNOSUPPRESSION PRODUCT WITH LOWEST MYCOPHENOLATE MOFETIL NHS ENGLAND NEW PATIENTS ONLY UNTIL FORMAL NICE NICE √* √* ONLY PROCUREMENT COST TO BE USED REPATRIATION AGREED TA481, TA482 TRANSPLANT IMMUNOSUPPRESSION PRODUCT WITH LOWEST MYCOPHENOLIC ACID NHS ENGLAND NEW PATIENTS ONLY UNTIL FORMAL NICE NICE √* √* ONLY PROCUREMENT COST TO BE USED REPATRIATION AGREED NELARABINE CANCER CDF CANCER EXCLUSION CDF POLICY CDF CDF SACT √ NERATINIB CANCER NHS ENGLAND CANCER EXCLUSION TA612 NICE NICE SACT √ √ NIRAPARIB CANCER CDF CANCER EXCLUSION CDF (TA 528) CDF CDF SACT √ √ TA 384, 400, 417, 462, 530 NICE NICE NIVOLUMAB CANCER NHS ENGLAND/CDF CANCER EXCLUSION CDF (TA 483, TA 484, TA 490, TA 558, TA SACT √ √ CDF CDF 581)

NHS England drugs-list v15 2020-2021.xlsx NHSE Commissioned PbRE Drugv15 11 31/03/2020 SUITABLE FOR SUITABLE FOR SPECIALIST SHARED CARE SHARED CARE CENTRE ONLY BETWEEN PRIOR WITH PRIMARY (includng SPECIALIST APPROVAL CARE (IF DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA STOPPING CRITERIA MONITORING/AUDIT REQUIREMENTS outreach when AND PROFORMA SUPPORTED BY delivered as part SECONDARY REQUIRED LOCAL of a provider CARE VIA PRESCRIBING network) NETWORK COMMITTEE) MODEL TA343 & 513 NICE NICE OBINUTUZUMAB CANCER NHS ENGLAND/CDF CANCER EXCLUSION SACT √ √ CDF (TA472) CDF CDF NICE NICE OLAPARIB CANCER NHS ENGLAND/CDF CANCER EXCLUSION TA 381, CDF TA598, TA620 SACT √ √ CDF CDF OSIMERTINIB CANCER CDF CANCER EXCLUSION CDF (TA 416) CDF CDF SACT √ √ NICE NICE PALBOCICLIB CANCER NHS ENGLAND/CDF CANCER EXCLUSION TA 495 & TA 619 (CDF) SACT √ √ CDF CDF PANITUMUMAB CANCER NHS ENGLAND CANCER EXCLUSION TA439 NICE NICE SACT √ √

PANOBINOSTAT CANCER NHS ENGLAND CANCER EXCLUSION TA 380 NICE NICE SACT √

PEGASPARGASE CANCER NHS ENGLAND CANCER EXCLUSION TA 408 NICE NICE SACT √

PEGYLATED LIPOSOMAL NHS ENGLAND/ TA91 NICE NICE CANCER CANCER EXCLUSION SACT √ DOXORUBICIN CDF CDF POLICY CDF CDF TA135, TA181, TA190, TA 402 PEMETREXED CANCER NHS ENGLAND CANCER EXCLUSION NICE NICE SACT √

PEPTIDE RECEPTOR CANCER CDF NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ RADIONUCLEOTIDE THERAPY

PERTUZUMAB CANCER NHS ENGLAND CANCER EXCLUSION NICE TA 424, TA 509 and TA 569 NICE NICE SACT √ √

PIXANTRONE CANCER NHS ENGLAND CANCER EXCLUSION TA306 NICE NICE SACT √

ENDOCRINOLOGY; NON-MALIGNANT PROTEIN KINASE INHIBITORS NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ CONDITIONS

RADIUM-223 DICHLORIDE CANCER NHS ENGLAND CANCER EXCLUSION NICE TA 376 replaced by TA 412 NICE NICE SACT √ √

NOT ROUTINELY COMMISSIONED - RAMUCIRUMAB CANCER NHS ENGLAND CANCER EXCLUSION AS PER IFR APPROVAL AS PER IFR APPROVAL SACT √ TA 378 NICE NICE RIBOCICLIB CANCER NHS ENGLAND/CDF CANCER EXCLUSION TA 496, CDF TA593 SACT √ √ CDF CDF RUCAPARIB CANCER NHS ENGLAND/CDF CANCER EXCLUSION CDF TA611 CDF CDF SACT √ √ ADENOSINE DEAMINASE DEFICIENCY- STRIMVELIS SEVERE COMBINED NHS ENGLAND ATMP HST7 NICE NICE NICE AUDIT √ IMMUNODEFICIENCY TA481, TA482 TRANSPLANT IMMUNOSUPPRESSION PRODUCT WITH LOWEST TACROLIMUS NHS ENGLAND NEW PATIENTS ONLY UNTIL FORMAL NICE NICE √* √* ONLY PROCUREMENT COST TO BE USED REPATRIATION AGREED TALIMOGENE LAHERPAREPVEC CANCER NHS ENGLAND CANCER EXCLUSION TA 410 NICE NICE SACT √ √ TA23 & TA121 NICE NICE TEMOZOLOMIDE CANCER NHS ENGLAND CANCER EXCLUSION SACT √ √ NHS ENGLAND POLICY 200203P NHS ENGLAND POLICY NHS ENGLAND POLICY ENDOCRINOLOGY; NON-MALIGNANT TEMOZOLOMIDE NHS ENGLAND CANCER EXCLUSION NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL AS PER IFR APPROVAL AS PER IFR APPROVAL √ CONDITIONS NICE NICE TISAGENLECLEUCEL CANCER CDF ATMP CDF (TA 554, TA 567) SACT √ √ CDF CDF TIVOZANIB CANCER NHS ENGLAND CANCER EXCLUSION TA 512 NICE NICE SACT √ √ TRABECTEDIN CANCER NHS ENGLAND ANTINEOPLASTIC DRUGS TA185 NICE NICE SACT √ TRAMETINIB CANCER NHS ENGLAND CANCER EXCLUSION TA 396 & TA 544 NICE NICE SACT √ √ TRASTUZUMAB CANCER NHSE ENGLAND CANCER EXCLUSION TA 34, 107, 208 NICE NICE SACT √ TRASTUZUMAB EMTANSINE CANCER NHS ENGLAND CANCER EXCLUSION TA 458 NICE NICE SACT √ √ TRIFLURIDINE–TIPIRACIL CANCER NHS ENGLAND CANCER EXCLUSION TA 405 NICE NICE SACT √ √ TREATMENT OF TOXIXITY WITH 5-FU NHS ENGLAND URGENT POLICY URIDINE TRIACETATE NHS ENGLAND CANCER EXCLUSION NHS ENGLAND POLICY NHS ENGLAND POLICY √ √ AND CAPECITABINE STATEMENT 1929 TA 487 NICE NICE VENETOCLAX CANCER NHS ENGLAND/CDF CANCER EXCLUSION SACT √ √ CDF CDF CDF

* DRUG IS BEING REPATRIATED FROM PRIMARY TO SECONDARY CARE THEREFORE SUPPLY ROUTE MAY VARY AT PRESENT

** ROUTINELY COMMISSIONED IN COMBINATION WHEN DUAL THERAPY REQUIRED

*** ONLY WHEN PRESCRIBED IN AN ADULT SPECIALIST CENTRE **** ONLY WHERE IT IS A RECOGNISED MS CENTRE WITH SPECIALIST NURSE SUPPORT

NEW LINES ADDED TO V15 LIST CHANGES TO V14 19/20 LIST

ADDITIONAL NOTES: 1. WHERE THE FUNDED INDICATION IS FOR PAEDIATRIC USE THE CCG WILL BECOME THE RESPONSIBLE COMMISSIONER WHEN THE PATIENT IS TRANSFERRED TO THE ADULT SERVICE 2. CCGS ARE THE RESPONSIBLE COMMISSIONER FOR RITUXIMAB IN ADULT NON CANCEROUS HAEMOTOLOGICAL CONDITIONS (EG ITP) AND NON SPECIALIST AUTO-INFLAMMATORY CONDITIONS (EG RA) 3. ELTROMBOPAG AND ROMIPLOSTIM ARE THE RESPONSIBILTY OF CCGS REGARDLESS OF THE CAUSE OF THE THROMBOCYTOPENIA IN ADULTS (PAEDIATRICS ARE NHS ENGLAND RESPONSIBILITY) 4. IT IS A MANDATED REQUIREMENT THAT ALL USE OF CHEMOTHERAPY IS RECORDED IN THE SACT DATABASE INCLUDING THOSE TREATMENTS FUNDED THROUGH THE CDF 5. USE IN VASCULAR DISEASE IS COMMISSIONED BY NHS ENGLAND WITHIN SPECIALIST CENTRES - CCG's ARE RESPONSIBLE FOR ALL OTHER INDICATIONS 6. NHS ENGLAND IS THE RESPONSIBLE COMMISSIONER WHEN SOMATROPIN ANALOGUES (GROWTH HORMONE) ARE PRESCRIBED IN SPECIALIST CENTRES FOR INDICATIONS FALLING OUTSIDE NICE GUIDANCE 7. NHS ENGLAND COMMISSIONS ARVS AS PER PUBLISHED POLICIES, FOR THE TREATMENT OF PEOPLE WITH DIAGNOSED HIV INFECTION AND FOR THOSE THOUGHT TO BE HIV POSITIVE (POST EXPOSURE PROPHYLAXIS). NHS ENGLAND DOES NOT ROUTINELY COMMISSION PRE-EXPOSURE PROPHYLAXIS AND THIS IS ONLY AVAILABLE TO THOSE ENROLLED IN CLINICAL STUDIES OR OTHER NHS ENGLAND AGREED SCHEMES

8.DRUGS APPROVED BY NICE FOR ADULT CONDITIONS WILL BE COMMISSIONED IN CHILDREN AT SPECIALISED PAEDIATRIC CENTRES IF THE PATIENT MEETS THE NICE CRITERIA AND THERE IS EVIDENCE TO SUGGEST THAT THE DRUG IS SAFE AND CLINICALLY APPROPRIATE TO USE IN CHILDREN AS PER THE NHS ENGLAND MEDICINES FOR CHILDREN POLICY FOUND AT https://www.england.nhs.uk/publication/commissioning-medicines-for-children-specialised-services/ AND A BLUETEQ FORM IS AVAILABLE. THIS INCLUDES FOR DRUGS NORMALLY COMMISISONED BY CCG'S IN ADULTS EG ADALIMUMAB, ETANERCEPT, INFLIXIMAB ETC PLEASE NOTE THAT MEDICINES FUNDED UNDER THE NHS ENGLAND MEDICINES FOR CHILDREN POLICY MAY HAVE ADDITIONAL CRITERIA WITH RESPECT TO ACCESS 9. PLEASE NOTE THIS IS A NOT LIVE LIST AND THE COMMISSIONING POSITION MAY CHANGE PRIOR TO A NEW LIST BEING PUBLISHED IN MARCH OF EACH YEAR - REFER TO THE NICE POLICY PROGRAMME ON THE NICE WEBSITE AND/OR THE NHS ENGLAND POLICY PROGRAMME PUBLSIHED AT https://www.england.nhs.uk/publication/clinical-commissioning-policy-work-programme/ 10. Products that are currently available via the Early Access to Medicines Scheme are not covered by this list but all require registration via the Blueteq system

NHS England drugs-list v15 2020-2021.xlsx NHSE Commissioned PbRE Drugv15 12 31/03/2020